bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
rehabilitation is an umlsterm, deaf is an umlsterm, adults is an umlsterm, deaf is an umlsterm, children is an umlsterm, cochlear implants is an umlsterm, treatment is an umlsterm, deafness is an umlsterm, development is an umlsterm, devices is an umlsterm, surgical is an umlsterm, technique is an umlsterm, hearing is an umlsterm, deaf is an umlsterm, adults is an umlsterm, telephone is an umlsterm, job is an umlsterm, deaf is an umlsterm, children is an umlsterm, schools is an umlsterm, cochlear implantation is an umlsterm, hearing is an umlsterm, rehabilitation is an umlsterm, training is an umlsterm, cochlea is an umlsterm, diagnosis is an umlsterm, temporal bone is an umlsterm, computerized tomography is an umlsterm, imaging is an umlsterm, temporal bone is an umlsterm, MRI is an umlsterm, technique is an umlsterm, postoperative is an umlsterm, X - ray is an umlsterm, projection is an umlsterm, electrode is an umlsterm, cochlea is an umlsterm	DerRadiologe.70370991.eng.abstr_task0	Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .	[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]	[ "umlsterm" ]
rehabilitation is an umlsterm, deaf is an umlsterm, adults is an umlsterm, deaf is an umlsterm, children is an umlsterm, cochlear implants is an umlsterm, treatment is an umlsterm, deafness is an umlsterm, development is an umlsterm, devices is an umlsterm, surgical is an umlsterm, technique is an umlsterm, hearing is an umlsterm, deaf is an umlsterm, adults is an umlsterm, telephone is an umlsterm, job is an umlsterm, deaf is an umlsterm, children is an umlsterm, schools is an umlsterm, cochlear implantation is an umlsterm, hearing is an umlsterm, rehabilitation is an umlsterm, training is an umlsterm, cochlea is an umlsterm, diagnosis is an umlsterm, temporal bone is an umlsterm, computerized tomography is an umlsterm, imaging is an umlsterm, temporal bone is an umlsterm, MRI is an umlsterm, technique is an umlsterm, postoperative is an umlsterm, X - ray is an umlsterm, projection is an umlsterm, electrode is an umlsterm, cochlea is an umlsterm	DerRadiologe.70370991.eng.abstr_task1	Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please typing these entity words according to sentence: rehabilitation, deaf, adults, deaf, children, cochlear implants, treatment, deafness, development, devices, surgical, technique, hearing, deaf, adults, telephone, job, deaf, children, schools, cochlear implantation, hearing, rehabilitation, training, cochlea, diagnosis, temporal bone, computerized tomography, imaging, temporal bone, MRI, technique, postoperative, X - ray, projection, electrode, cochlea Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .	[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]	[ "umlsterm" ]
rehabilitation, deaf, adults, deaf, children, cochlear implants, treatment, deafness, development, devices, surgical, technique, hearing, deaf, adults, telephone, job, deaf, children, schools, cochlear implantation, hearing, rehabilitation, training, cochlea, diagnosis, temporal bone, computerized tomography, imaging, temporal bone, MRI, technique, postoperative, X - ray, projection, electrode, cochlea	DerRadiologe.70370991.eng.abstr_task2	Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .	[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]	[ "umlsterm" ]
transdermal glyceryl trinitrate is a Intervention_Pharmacological, failure of intravenous infusion is a Outcome_Physical, phlebitis and extravasation is a Participant_Condition, placebo patches is a Intervention_Control, Headaches is a Outcome_Physical, analgesics is a Intervention_Pharmacological	73896_task0	Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]	Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .	[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]
transdermal glyceryl trinitrate is a Intervention_Pharmacological, failure of intravenous infusion is a Outcome_Physical, phlebitis and extravasation is a Participant_Condition, placebo patches is a Intervention_Control, Headaches is a Outcome_Physical, analgesics is a Intervention_Pharmacological	73896_task1	Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please typing these entity words according to sentence: transdermal glyceryl trinitrate, failure of intravenous infusion, phlebitis and extravasation, placebo patches, Headaches, analgesics Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]	Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .	[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]
transdermal glyceryl trinitrate, failure of intravenous infusion, phlebitis and extravasation, placebo patches, Headaches, analgesics	73896_task2	Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]	Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .	[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]
tumor necrosis factor - alpha is a Protein, TNF - alpha is a Protein, interleukin-1 beta is a Protein, IL-1 beta is a Protein, vascular cell adhesion molecule-1 is a Protein, VCAM-1 is a Protein, CD106 is a Protein, E - selectin is a Protein, ELAM-1 is a Protein, CD62E is a Protein, intercellular adhesion molecule-1 is a Protein, ICAM-1 is a Protein, CD54 is a Protein, VCAM-1 is a Protein, E - selectin is a Protein, TNF - alpha is a Protein, IL-1 beta is a Protein, TNF - alpha is a Protein	762_task0	Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.	[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]	[ "Protein" ]
tumor necrosis factor - alpha is a Protein, TNF - alpha is a Protein, interleukin-1 beta is a Protein, IL-1 beta is a Protein, vascular cell adhesion molecule-1 is a Protein, VCAM-1 is a Protein, CD106 is a Protein, E - selectin is a Protein, ELAM-1 is a Protein, CD62E is a Protein, intercellular adhesion molecule-1 is a Protein, ICAM-1 is a Protein, CD54 is a Protein, VCAM-1 is a Protein, E - selectin is a Protein, TNF - alpha is a Protein, IL-1 beta is a Protein, TNF - alpha is a Protein	762_task1	Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please typing these entity words according to sentence: tumor necrosis factor - alpha, TNF - alpha, interleukin-1 beta, IL-1 beta, vascular cell adhesion molecule-1, VCAM-1, CD106, E - selectin, ELAM-1, CD62E, intercellular adhesion molecule-1, ICAM-1, CD54, VCAM-1, E - selectin, TNF - alpha, IL-1 beta, TNF - alpha Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.	[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]	[ "Protein" ]
tumor necrosis factor - alpha, TNF - alpha, interleukin-1 beta, IL-1 beta, vascular cell adhesion molecule-1, VCAM-1, CD106, E - selectin, ELAM-1, CD62E, intercellular adhesion molecule-1, ICAM-1, CD54, VCAM-1, E - selectin, TNF - alpha, IL-1 beta, TNF - alpha	762_task2	Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.	[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]	[ "Protein" ]
Patienten is an umlsterm, Spaetlaehmung is an umlsterm, elektroneurographisch is an umlsterm	DerUnfallchirurg.60990784.ger.abstr_task0	Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .	[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Spaetlaehmung is an umlsterm, elektroneurographisch is an umlsterm	DerUnfallchirurg.60990784.ger.abstr_task1	Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please typing these entity words according to sentence: Patienten, Spaetlaehmung, elektroneurographisch Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .	[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]	[ "umlsterm" ]
Patienten, Spaetlaehmung, elektroneurographisch	DerUnfallchirurg.60990784.ger.abstr_task2	Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .	[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]	[ "umlsterm" ]
HP1 chromodomain is a protein-domain, histone H3 is a protein-family, lysine 9 is an amino-acid, methyllysine is an amino-acid	1.0alpha7.train.881_task0	Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: amino-acid, protein-domain, protein-family	[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).	[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]	[ "protein-domain", "amino-acid", "protein-family", "protein" ]
HP1 chromodomain is a protein-domain, histone H3 is a protein-family, lysine 9 is an amino-acid, methyllysine is an amino-acid	1.0alpha7.train.881_task1	Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please typing these entity words according to sentence: HP1 chromodomain, histone H3, lysine 9, methyllysine Options: amino-acid, protein-domain, protein-family	[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).	[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]	[ "protein-domain", "amino-acid", "protein-family", "protein" ]
HP1 chromodomain, histone H3, lysine 9, methyllysine	1.0alpha7.train.881_task2	Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).	[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]	[ "protein-domain", "amino-acid", "protein-family", "protein" ]
CLR16.2 is a Protein, NBD / LRR family is a Protein, T cell is a Cell, function is a Function, mammalian is a Eukaryote, CATERPILLER ( NOD , NALP , PAN ) family is a Protein, proteins is a Protein, NBD - LRR superfamily is a Protein, plant is a Eukaryote, disease resistance ( R ) proteins is a Protein, function is a Function, cloning is a ExperimentalMethod, CATERPILLER gene is a Gene, CLR16.2 is a Gene, human is a Eukaryote, chromosome 16 is a Chromosome, protein is a Protein, gene is a Gene, NBD - LRR configuration is a Protein, CLR16.2 is a Gene, T lymphocytes is a Cell, Cellular is a Cell, CLR16.2 is a Protein, cytoplasmic is a CellComponent, protein is a Protein, CLR16.2 is a Protein, anti - CD3 is a Protein, anti - CD28 is a Protein, primary T lymphocytes is a Cell, T cell is a Cell, CLR16.2 is a Protein, NF - kappaB is a Protein, NFAT is a Protein, AP-1 is a Protein, reporter gene constructs is a ReporterGeneConstruction, T cell is a AP2EREBPRelatedDomain, anti - CD3 is a Protein, anti - CD28 is a Protein, antibodies is a Protein, PMA is a Protein, ionomycin is a Protein, T cell is a Cell, CLR16.2 is a Protein, transcripts is a Transcript, IL-2 is a Protein, CD25 proteins is a Protein, T cell is a Cell, IkappaBalpha is a AP2EREBPRelatedDomain, CLR16.2 is a Protein, T cell is a Cell, TCR is a Protein, co - stimulatory molecules is a MolecularEntity, T cell is a Cell, cellular is a Cell	81_task0	Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ReporterGeneConstruction, Function, ExperimentalMethod, CellComponent, Chromosome, Gene, AP2EREBPRelatedDomain, Transcript, MolecularEntity, Eukaryote, Protein, Cell	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]	CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.	[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]	[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]
CLR16.2 is a Protein, NBD / LRR family is a Protein, T cell is a Cell, function is a Function, mammalian is a Eukaryote, CATERPILLER ( NOD , NALP , PAN ) family is a Protein, proteins is a Protein, NBD - LRR superfamily is a Protein, plant is a Eukaryote, disease resistance ( R ) proteins is a Protein, function is a Function, cloning is a ExperimentalMethod, CATERPILLER gene is a Gene, CLR16.2 is a Gene, human is a Eukaryote, chromosome 16 is a Chromosome, protein is a Protein, gene is a Gene, NBD - LRR configuration is a Protein, CLR16.2 is a Gene, T lymphocytes is a Cell, Cellular is a Cell, CLR16.2 is a Protein, cytoplasmic is a CellComponent, protein is a Protein, CLR16.2 is a Protein, anti - CD3 is a Protein, anti - CD28 is a Protein, primary T lymphocytes is a Cell, T cell is a Cell, CLR16.2 is a Protein, NF - kappaB is a Protein, NFAT is a Protein, AP-1 is a Protein, reporter gene constructs is a ReporterGeneConstruction, T cell is a AP2EREBPRelatedDomain, anti - CD3 is a Protein, anti - CD28 is a Protein, antibodies is a Protein, PMA is a Protein, ionomycin is a Protein, T cell is a Cell, CLR16.2 is a Protein, transcripts is a Transcript, IL-2 is a Protein, CD25 proteins is a Protein, T cell is a Cell, IkappaBalpha is a AP2EREBPRelatedDomain, CLR16.2 is a Protein, T cell is a Cell, TCR is a Protein, co - stimulatory molecules is a MolecularEntity, T cell is a Cell, cellular is a Cell	81_task1	Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please typing these entity words according to sentence: CLR16.2, NBD / LRR family, T cell, function, mammalian, CATERPILLER ( NOD , NALP , PAN ) family, proteins, NBD - LRR superfamily, plant, disease resistance ( R ) proteins, function, cloning, CATERPILLER gene, CLR16.2, human, chromosome 16, protein, gene, NBD - LRR configuration, CLR16.2, T lymphocytes, Cellular, CLR16.2, cytoplasmic, protein, CLR16.2, anti - CD3, anti - CD28, primary T lymphocytes, T cell, CLR16.2, NF - kappaB, NFAT, AP-1, reporter gene constructs, T cell, anti - CD3, anti - CD28, antibodies, PMA, ionomycin, T cell, CLR16.2, transcripts, IL-2, CD25 proteins, T cell, IkappaBalpha, CLR16.2, T cell, TCR, co - stimulatory molecules, T cell, cellular Options: ReporterGeneConstruction, Function, ExperimentalMethod, CellComponent, Chromosome, Gene, AP2EREBPRelatedDomain, Transcript, MolecularEntity, Eukaryote, Protein, Cell	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]	CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.	[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]	[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]
CLR16.2, NBD / LRR family, T cell, function, mammalian, CATERPILLER ( NOD , NALP , PAN ) family, proteins, NBD - LRR superfamily, plant, disease resistance ( R ) proteins, function, cloning, CATERPILLER gene, CLR16.2, human, chromosome 16, protein, gene, NBD - LRR configuration, CLR16.2, T lymphocytes, Cellular, CLR16.2, cytoplasmic, protein, CLR16.2, anti - CD3, anti - CD28, primary T lymphocytes, T cell, CLR16.2, NF - kappaB, NFAT, AP-1, reporter gene constructs, T cell, anti - CD3, anti - CD28, antibodies, PMA, ionomycin, T cell, CLR16.2, transcripts, IL-2, CD25 proteins, T cell, IkappaBalpha, CLR16.2, T cell, TCR, co - stimulatory molecules, T cell, cellular	81_task2	Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]	CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.	[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]	[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]
Pyk2 is a protein, Grb2 is a protein, Shc is a protein, ERK2 is a protein	1.0alpha7.train.647_task0	Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.	[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]	[ "protein", "cell" ]
Pyk2 is a protein, Grb2 is a protein, Shc is a protein, ERK2 is a protein	1.0alpha7.train.647_task1	Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please typing these entity words according to sentence: Pyk2, Grb2, Shc, ERK2 Options: protein	[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.	[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]	[ "protein", "cell" ]
Pyk2, Grb2, Shc, ERK2	1.0alpha7.train.647_task2	Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please extract entity words from the input sentence	[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.	[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]	[ "protein", "cell" ]
Cardiolipin is a CHEMICAL	23172229_task0	Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.	[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Cardiolipin is a CHEMICAL	23172229_task1	Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please typing these entity words according to sentence: Cardiolipin Options: CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.	[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Cardiolipin	23172229_task2	Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.	[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Monocytic differentiation is an other_name, HL-60 promyelocytic leukemia cells is a cell_line	54876_task0	Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, other_name	[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]	Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.	[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]	[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]
Monocytic differentiation is an other_name, HL-60 promyelocytic leukemia cells is a cell_line	54876_task1	Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please typing these entity words according to sentence: Monocytic differentiation, HL-60 promyelocytic leukemia cells Options: cell_line, other_name	[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]	Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.	[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]	[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]
Monocytic differentiation, HL-60 promyelocytic leukemia cells	54876_task2	Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]	Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.	[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]	[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]
Silvia is a NOMBRE_SUJETO_ASISTENCIA, Pinal Guzman is a NOMBRE_SUJETO_ASISTENCIA, 8034756 is a ID_SUJETO_ASISTENCIA, 34 856758 37 is a ID_ASEGURAMIENTO, C/ Aviacion Española , 13 is a CALLE, Barañain is a TERRITORIO, 31010 is a TERRITORIO, 04/08/1981 is a FECHAS, España is a PAIS, 36 años is a EDAD_SUJETO_ASISTENCIA, 28/05/2018 is a FECHAS, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, 31 31 25230 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 36 años is a EDAD_SUJETO_ASISTENCIA, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, Clínica Hospital Virgen del Camino is a HOSPITAL, Ronda Cendea de Zizur , 58 - 2ºC is a CALLE, 31010 is a TERRITORIO, Barañain is a TERRITORIO, Navarra is a TERRITORIO, drarociomilena@hotmail.com is a CORREO_ELECTRONICO	410_task0	Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Silvia is a NOMBRE_SUJETO_ASISTENCIA, Pinal Guzman is a NOMBRE_SUJETO_ASISTENCIA, 8034756 is a ID_SUJETO_ASISTENCIA, 34 856758 37 is a ID_ASEGURAMIENTO, C/ Aviacion Española , 13 is a CALLE, Barañain is a TERRITORIO, 31010 is a TERRITORIO, 04/08/1981 is a FECHAS, España is a PAIS, 36 años is a EDAD_SUJETO_ASISTENCIA, 28/05/2018 is a FECHAS, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, 31 31 25230 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 36 años is a EDAD_SUJETO_ASISTENCIA, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, Clínica Hospital Virgen del Camino is a HOSPITAL, Ronda Cendea de Zizur , 58 - 2ºC is a CALLE, 31010 is a TERRITORIO, Barañain is a TERRITORIO, Navarra is a TERRITORIO, drarociomilena@hotmail.com is a CORREO_ELECTRONICO	410_task1	Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please typing these entity words according to sentence: Silvia, Pinal Guzman, 8034756, 34 856758 37, C/ Aviacion Española , 13, Barañain, 31010, 04/08/1981, España, 36 años, 28/05/2018, Rocío Milena Pabón Meneses, 31 31 25230, Mujer, 36 años, Rocío Milena Pabón Meneses, Clínica Hospital Virgen del Camino, Ronda Cendea de Zizur , 58 - 2ºC, 31010, Barañain, Navarra, drarociomilena@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Silvia, Pinal Guzman, 8034756, 34 856758 37, C/ Aviacion Española , 13, Barañain, 31010, 04/08/1981, España, 36 años, 28/05/2018, Rocío Milena Pabón Meneses, 31 31 25230, Mujer, 36 años, Rocío Milena Pabón Meneses, Clínica Hospital Virgen del Camino, Ronda Cendea de Zizur , 58 - 2ºC, 31010, Barañain, Navarra, drarociomilena@hotmail.com	410_task2	Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
antioxidants is an other_organic_compound, tumor necrosis factor - alpha is a protein_molecule, IL - beta is a protein_molecule, IL-6 is a protein_molecule, human peripheral blood mononuclear cells is a cell_type	12992_task0	Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_type, protein_molecule	[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.	[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]	[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]
antioxidants is an other_organic_compound, tumor necrosis factor - alpha is a protein_molecule, IL - beta is a protein_molecule, IL-6 is a protein_molecule, human peripheral blood mononuclear cells is a cell_type	12992_task1	Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please typing these entity words according to sentence: antioxidants, tumor necrosis factor - alpha, IL - beta, IL-6, human peripheral blood mononuclear cells Options: other_organic_compound, cell_type, protein_molecule	[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.	[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]	[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]
antioxidants, tumor necrosis factor - alpha, IL - beta, IL-6, human peripheral blood mononuclear cells	12992_task2	Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please extract entity words from the input sentence	[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.	[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]	[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]
ADAM 12 is a protein, p85alpha is a protein, phosphatidylinositol 3-kinase is a protein	HPRD50.d11_task0	Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]	Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells	[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]	[ "protein" ]
ADAM 12 is a protein, p85alpha is a protein, phosphatidylinositol 3-kinase is a protein	HPRD50.d11_task1	Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please typing these entity words according to sentence: ADAM 12, p85alpha, phosphatidylinositol 3-kinase Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]	Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells	[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]	[ "protein" ]
ADAM 12, p85alpha, phosphatidylinositol 3-kinase	HPRD50.d11_task2	Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]	Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells	[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]	[ "protein" ]
factor VIIa is a Protein, coagulation factor VII is a Protein, factor VIIa is a Protein, factor X is a Protein, factor IX is a Protein, tissue factor is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, asparagine residues is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, Asparagine residues 145 is a Entity, 322 is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, asparagine residue 322 is a Entity, asparagine residue 145 is a Entity, factor VIIa is a Protein	515_task0	Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)	[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
factor VIIa is a Protein, coagulation factor VII is a Protein, factor VIIa is a Protein, factor X is a Protein, factor IX is a Protein, tissue factor is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, asparagine residues is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, Asparagine residues 145 is a Entity, 322 is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, asparagine residue 322 is a Entity, asparagine residue 145 is a Entity, factor VIIa is a Protein	515_task1	Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please typing these entity words according to sentence: factor VIIa, coagulation factor VII, factor VIIa, factor X, factor IX, tissue factor, factor VIIa, aspartic acid residue, asparagine residues, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, Asparagine residues 145, 322, factor VIIa, factor VIIa, asparagine residue 322, asparagine residue 145, factor VIIa Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)	[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
factor VIIa, coagulation factor VII, factor VIIa, factor X, factor IX, tissue factor, factor VIIa, aspartic acid residue, asparagine residues, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, Asparagine residues 145, 322, factor VIIa, factor VIIa, asparagine residue 322, asparagine residue 145, factor VIIa	515_task2	Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)	[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]	[ "Entity", "Protein" ]
Thorax is an umlsterm, Lymphome is an umlsterm, Lungenerkrankungen is an umlsterm, Pulmonalembolien is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Bronchoskopie is an umlsterm	DerRadiologe.60360457.ger.abstr_task0	Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .	[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]	[ "umlsterm" ]
Thorax is an umlsterm, Lymphome is an umlsterm, Lungenerkrankungen is an umlsterm, Pulmonalembolien is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Bronchoskopie is an umlsterm	DerRadiologe.60360457.ger.abstr_task1	Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please typing these entity words according to sentence: Thorax, Lymphome, Lungenerkrankungen, Pulmonalembolien, Diagnostik, Pathologie, Bronchoskopie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .	[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]	[ "umlsterm" ]
Thorax, Lymphome, Lungenerkrankungen, Pulmonalembolien, Diagnostik, Pathologie, Bronchoskopie	DerRadiologe.60360457.ger.abstr_task2	Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .	[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]	[ "umlsterm" ]
in vitro is an umlsterm, Kirschner - Draehte is an umlsterm	DerUnfallchirurg.01030839.ger.abstr_task0	Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .	[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]	[ "umlsterm" ]
in vitro is an umlsterm, Kirschner - Draehte is an umlsterm	DerUnfallchirurg.01030839.ger.abstr_task1	Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please typing these entity words according to sentence: in vitro, Kirschner - Draehte Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .	[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]	[ "umlsterm" ]
in vitro, Kirschner - Draehte	DerUnfallchirurg.01030839.ger.abstr_task2	Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .	[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]	[ "umlsterm" ]
skin cancer is a Outcome_Physical, adults : is a Participant_Age, mailed , tailored intervention is a Intervention_Educational, skin self - examination behaviors is a Outcome_Mental, moderate and high risk for skin cancer is a Participant_Condition, Adults is a Participant_Age, tailored materials , including personalized risk feedback is a Intervention_Educational, general educational materials is a Intervention_Educational, sun protection is a Outcome_Mental, 596 is a Participant_Sample-size, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination is a Outcome_Mental, Tailored communications is a Intervention_Educational, sun - protection behaviors is a Outcome_Mental, increased risk for skin cancer is a Participant_Condition	44540_task0	Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .	[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]
skin cancer is a Outcome_Physical, adults : is a Participant_Age, mailed , tailored intervention is a Intervention_Educational, skin self - examination behaviors is a Outcome_Mental, moderate and high risk for skin cancer is a Participant_Condition, Adults is a Participant_Age, tailored materials , including personalized risk feedback is a Intervention_Educational, general educational materials is a Intervention_Educational, sun protection is a Outcome_Mental, 596 is a Participant_Sample-size, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination is a Outcome_Mental, Tailored communications is a Intervention_Educational, sun - protection behaviors is a Outcome_Mental, increased risk for skin cancer is a Participant_Condition	44540_task1	Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please typing these entity words according to sentence: skin cancer, adults :, mailed , tailored intervention, skin self - examination behaviors, moderate and high risk for skin cancer, Adults, tailored materials , including personalized risk feedback, general educational materials, sun protection, 596, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination, Tailored communications, sun - protection behaviors, increased risk for skin cancer Options: Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .	[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]
skin cancer, adults :, mailed , tailored intervention, skin self - examination behaviors, moderate and high risk for skin cancer, Adults, tailored materials , including personalized risk feedback, general educational materials, sun protection, 596, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination, Tailored communications, sun - protection behaviors, increased risk for skin cancer	44540_task2	Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .	[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]
H-1 histone is a Protein, histones is a Protein, histone H-1 is a Protein, histone is a Protein, histones is a Protein, histone H-3 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, histone is a Protein, histone is a Protein, histone is a Protein	507_task0	Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.	[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]	[ "Protein" ]
H-1 histone is a Protein, histones is a Protein, histone H-1 is a Protein, histone is a Protein, histones is a Protein, histone H-3 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, histone is a Protein, histone is a Protein, histone is a Protein	507_task1	Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please typing these entity words according to sentence: H-1 histone, histones, histone H-1, histone, histones, histone H-3, H-1, H-1, H-1, H-1, histone, histone, histone Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.	[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]	[ "Protein" ]
H-1 histone, histones, histone H-1, histone, histones, histone H-3, H-1, H-1, H-1, H-1, histone, histone, histone	507_task2	Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.	[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]	[ "Protein" ]
open is an umlsterm, surgery is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, syndrome is an umlsterm, development is an umlsterm, methods is an umlsterm, treatment is an umlsterm, disc prolapses is an umlsterm, procedures is an umlsterm, diagnostic is an umlsterm, therapy is an umlsterm, methods is an umlsterm, fenestration is an umlsterm, chemonucleolysis is an umlsterm, methods is an umlsterm, laser is an umlsterm, procedures is an umlsterm, procedures is an umlsterm, control groups is an umlsterm, therapy is an umlsterm, methods is an umlsterm, retrospective studies is an umlsterm, single is an umlsterm, method is an umlsterm, criteria is an umlsterm, study design is an umlsterm, procedures is an umlsterm, disorders is an umlsterm, criteria is an umlsterm, time is an umlsterm, methods is an umlsterm, procedures is an umlsterm	DerOrthopaede.90280598.eng.abstr_task0	Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .	[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]	[ "umlsterm" ]
open is an umlsterm, surgery is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, syndrome is an umlsterm, development is an umlsterm, methods is an umlsterm, treatment is an umlsterm, disc prolapses is an umlsterm, procedures is an umlsterm, diagnostic is an umlsterm, therapy is an umlsterm, methods is an umlsterm, fenestration is an umlsterm, chemonucleolysis is an umlsterm, methods is an umlsterm, laser is an umlsterm, procedures is an umlsterm, procedures is an umlsterm, control groups is an umlsterm, therapy is an umlsterm, methods is an umlsterm, retrospective studies is an umlsterm, single is an umlsterm, method is an umlsterm, criteria is an umlsterm, study design is an umlsterm, procedures is an umlsterm, disorders is an umlsterm, criteria is an umlsterm, time is an umlsterm, methods is an umlsterm, procedures is an umlsterm	DerOrthopaede.90280598.eng.abstr_task1	Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please typing these entity words according to sentence: open, surgery, complications, open, surgery, syndrome, development, methods, treatment, disc prolapses, procedures, diagnostic, therapy, methods, fenestration, chemonucleolysis, methods, laser, procedures, procedures, control groups, therapy, methods, retrospective studies, single, method, criteria, study design, procedures, disorders, criteria, time, methods, procedures Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .	[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]	[ "umlsterm" ]
open, surgery, complications, open, surgery, syndrome, development, methods, treatment, disc prolapses, procedures, diagnostic, therapy, methods, fenestration, chemonucleolysis, methods, laser, procedures, procedures, control groups, therapy, methods, retrospective studies, single, method, criteria, study design, procedures, disorders, criteria, time, methods, procedures	DerOrthopaede.90280598.eng.abstr_task2	Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .	[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]	[ "umlsterm" ]
beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA	416_task0	Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).	[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]	[ "Gene/protein/RNA" ]
beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA	416_task1	Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please typing these entity words according to sentence: beta - catenin, E - cadherin, alpha - catenin Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).	[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]	[ "Gene/protein/RNA" ]
beta - catenin, E - cadherin, alpha - catenin	416_task2	Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).	[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]	[ "Gene/protein/RNA" ]
Erythroid gene expression is an other_name, erythropoietin is a protein_molecule, haemin is an other_organic_compound, delta - aminolaevulinic acid is an other_organic_compound, UT-7 cells is a cell_line	42970_task0	Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_line, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]	Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.	[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]	[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]
Erythroid gene expression is an other_name, erythropoietin is a protein_molecule, haemin is an other_organic_compound, delta - aminolaevulinic acid is an other_organic_compound, UT-7 cells is a cell_line	42970_task1	Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please typing these entity words according to sentence: Erythroid gene expression, erythropoietin, haemin, delta - aminolaevulinic acid, UT-7 cells Options: other_organic_compound, cell_line, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]	Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.	[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]	[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]
Erythroid gene expression, erythropoietin, haemin, delta - aminolaevulinic acid, UT-7 cells	42970_task2	Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]	Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.	[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]	[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]
training is an umlsterm, patients is an umlsterm, stages is an umlsterm, disease is an umlsterm, patient is an umlsterm, diagnosis is an umlsterm, mobilization is an umlsterm, depressive symptoms is an umlsterm	ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task0	Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .	[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]	[ "umlsterm" ]
training is an umlsterm, patients is an umlsterm, stages is an umlsterm, disease is an umlsterm, patient is an umlsterm, diagnosis is an umlsterm, mobilization is an umlsterm, depressive symptoms is an umlsterm	ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task1	Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please typing these entity words according to sentence: training, patients, stages, disease, patient, diagnosis, mobilization, depressive symptoms Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .	[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]	[ "umlsterm" ]
training, patients, stages, disease, patient, diagnosis, mobilization, depressive symptoms	ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task2	Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .	[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]	[ "umlsterm" ]
Periduralanalgesie is an umlsterm, Komplikationen is an umlsterm, erwachsenen is an umlsterm, Patienten is an umlsterm, Verwendung is an umlsterm, Kombinationsloesung is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Trauma is an umlsterm, Darmfunktion is an umlsterm, Nausea is an umlsterm, Juckreiz is an umlsterm, Patienten is an umlsterm, Muskelschwaeche is an umlsterm, Beine is an umlsterm, Komplikationen is an umlsterm, Patient is an umlsterm, Hypoxie is an umlsterm, Boden is an umlsterm, Minderperfusion is an umlsterm, Patienten is an umlsterm, Haematome is an umlsterm, Abszesse is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Komplikationen is an umlsterm, Auge is an umlsterm	DerUrologeA.00390041.ger.abstr_task0	Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .	[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]	[ "umlsterm" ]
Periduralanalgesie is an umlsterm, Komplikationen is an umlsterm, erwachsenen is an umlsterm, Patienten is an umlsterm, Verwendung is an umlsterm, Kombinationsloesung is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Trauma is an umlsterm, Darmfunktion is an umlsterm, Nausea is an umlsterm, Juckreiz is an umlsterm, Patienten is an umlsterm, Muskelschwaeche is an umlsterm, Beine is an umlsterm, Komplikationen is an umlsterm, Patient is an umlsterm, Hypoxie is an umlsterm, Boden is an umlsterm, Minderperfusion is an umlsterm, Patienten is an umlsterm, Haematome is an umlsterm, Abszesse is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Komplikationen is an umlsterm, Auge is an umlsterm	DerUrologeA.00390041.ger.abstr_task1	Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please typing these entity words according to sentence: Periduralanalgesie, Komplikationen, erwachsenen, Patienten, Verwendung, Kombinationsloesung, Analgesie, Patientenzufriedenheit, Trauma, Darmfunktion, Nausea, Juckreiz, Patienten, Muskelschwaeche, Beine, Komplikationen, Patient, Hypoxie, Boden, Minderperfusion, Patienten, Haematome, Abszesse, Analgesie, Patientenzufriedenheit, Komplikationen, Auge Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .	[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]	[ "umlsterm" ]
Periduralanalgesie, Komplikationen, erwachsenen, Patienten, Verwendung, Kombinationsloesung, Analgesie, Patientenzufriedenheit, Trauma, Darmfunktion, Nausea, Juckreiz, Patienten, Muskelschwaeche, Beine, Komplikationen, Patient, Hypoxie, Boden, Minderperfusion, Patienten, Haematome, Abszesse, Analgesie, Patientenzufriedenheit, Komplikationen, Auge	DerUrologeA.00390041.ger.abstr_task2	Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .	[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]	[ "umlsterm" ]
disease is an umlsterm, erythema is an umlsterm, oedema is an umlsterm, face is an umlsterm, literature is an umlsterm, lymphoedema is an umlsterm, oedema is an umlsterm, acne is an umlsterm, rosacea is an umlsterm, laboratory is an umlsterm, findings is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm	DerHautarzt.50460796.eng.abstr_task0	Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .	[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]	[ "umlsterm" ]
disease is an umlsterm, erythema is an umlsterm, oedema is an umlsterm, face is an umlsterm, literature is an umlsterm, lymphoedema is an umlsterm, oedema is an umlsterm, acne is an umlsterm, rosacea is an umlsterm, laboratory is an umlsterm, findings is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm	DerHautarzt.50460796.eng.abstr_task1	Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please typing these entity words according to sentence: disease, erythema, oedema, face, literature, lymphoedema, oedema, acne, rosacea, laboratory, findings, therapeutic, measures Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .	[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]	[ "umlsterm" ]
disease, erythema, oedema, face, literature, lymphoedema, oedema, acne, rosacea, laboratory, findings, therapeutic, measures	DerHautarzt.50460796.eng.abstr_task2	Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .	[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]	[ "umlsterm" ]
nitric oxide is an umlsterm, vasodilatation is an umlsterm, relaxation is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, platelet aggregation is an umlsterm, Animal experiments is an umlsterm, production is an umlsterm, pregnancy is an umlsterm, vascular resistance is an umlsterm, glomerular filtration rate is an umlsterm, Inhibition is an umlsterm, preeclampsia - like is an umlsterm, syndrome is an umlsterm, animal is an umlsterm, in vitro is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, deficiency is an umlsterm, vasoconstriction is an umlsterm, preeclampsia is an umlsterm, half - life is an umlsterm, time is an umlsterm, drugs is an umlsterm, glycerol is an umlsterm, nitroglycerine is an umlsterm, isosorbide dinitrate is an umlsterm, ISDN is an umlsterm, isosorbide mononitrate is an umlsterm, use is an umlsterm, donors is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, knowledge is an umlsterm, pregnancy is an umlsterm, minor is an umlsterm, blood pressure is an umlsterm, perfusion is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, prophylaxis is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, women is an umlsterm, risk is an umlsterm, development is an umlsterm, disease is an umlsterm, sample size is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, literature is an umlsterm, use is an umlsterm, donors is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, clinical trials is an umlsterm	DerGynaekologe.90320768.eng.abstr_task0	Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .	[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]	[ "umlsterm" ]
nitric oxide is an umlsterm, vasodilatation is an umlsterm, relaxation is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, platelet aggregation is an umlsterm, Animal experiments is an umlsterm, production is an umlsterm, pregnancy is an umlsterm, vascular resistance is an umlsterm, glomerular filtration rate is an umlsterm, Inhibition is an umlsterm, preeclampsia - like is an umlsterm, syndrome is an umlsterm, animal is an umlsterm, in vitro is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, deficiency is an umlsterm, vasoconstriction is an umlsterm, preeclampsia is an umlsterm, half - life is an umlsterm, time is an umlsterm, drugs is an umlsterm, glycerol is an umlsterm, nitroglycerine is an umlsterm, isosorbide dinitrate is an umlsterm, ISDN is an umlsterm, isosorbide mononitrate is an umlsterm, use is an umlsterm, donors is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, knowledge is an umlsterm, pregnancy is an umlsterm, minor is an umlsterm, blood pressure is an umlsterm, perfusion is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, prophylaxis is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, women is an umlsterm, risk is an umlsterm, development is an umlsterm, disease is an umlsterm, sample size is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, literature is an umlsterm, use is an umlsterm, donors is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, clinical trials is an umlsterm	DerGynaekologe.90320768.eng.abstr_task1	Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please typing these entity words according to sentence: nitric oxide, vasodilatation, relaxation, smooth muscle, cells, platelet aggregation, Animal experiments, production, pregnancy, vascular resistance, glomerular filtration rate, Inhibition, preeclampsia - like, syndrome, animal, in vitro, human, pregnancy, deficiency, vasoconstriction, preeclampsia, half - life, time, drugs, glycerol, nitroglycerine, isosorbide dinitrate, ISDN, isosorbide mononitrate, use, donors, human, pregnancy, knowledge, pregnancy, minor, blood pressure, perfusion, patients, preeclampsia, prophylaxis, preeclampsia, donors, women, risk, development, disease, sample size, therapy, preeclampsia, donors, literature, use, donors, prophylaxis, therapy, preeclampsia, clinical trials Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .	[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]	[ "umlsterm" ]
nitric oxide, vasodilatation, relaxation, smooth muscle, cells, platelet aggregation, Animal experiments, production, pregnancy, vascular resistance, glomerular filtration rate, Inhibition, preeclampsia - like, syndrome, animal, in vitro, human, pregnancy, deficiency, vasoconstriction, preeclampsia, half - life, time, drugs, glycerol, nitroglycerine, isosorbide dinitrate, ISDN, isosorbide mononitrate, use, donors, human, pregnancy, knowledge, pregnancy, minor, blood pressure, perfusion, patients, preeclampsia, prophylaxis, preeclampsia, donors, women, risk, development, disease, sample size, therapy, preeclampsia, donors, literature, use, donors, prophylaxis, therapy, preeclampsia, clinical trials	DerGynaekologe.90320768.eng.abstr_task2	Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .	[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]	[ "umlsterm" ]
glucagon receptor is a GENE-Y, G protein - coupled receptors is a GENE-N, glucagon is a GENE-Y, GIP is a GENE-Y, GLP-1 is a GENE-Y, GLP-2 receptors is a GENE-Y	12529935_task0	Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.	[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glucagon receptor is a GENE-Y, G protein - coupled receptors is a GENE-N, glucagon is a GENE-Y, GIP is a GENE-Y, GLP-1 is a GENE-Y, GLP-2 receptors is a GENE-Y	12529935_task1	Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please typing these entity words according to sentence: glucagon receptor, G protein - coupled receptors, glucagon, GIP, GLP-1, GLP-2 receptors Options: GENE-Y, GENE-N	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.	[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glucagon receptor, G protein - coupled receptors, glucagon, GIP, GLP-1, GLP-2 receptors	12529935_task2	Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.	[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
protease is a protein, ammonium is a compound, sulfate is a compound	DS.d4_task0	Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.	[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]	[ "protein", "compound" ]
protease is a protein, ammonium is a compound, sulfate is a compound	DS.d4_task1	Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please typing these entity words according to sentence: protease, ammonium, sulfate Options: compound, protein	[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.	[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]	[ "protein", "compound" ]
protease, ammonium, sulfate	DS.d4_task2	Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please extract entity words from the input sentence	[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.	[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]	[ "protein", "compound" ]
Kombinationstherapie is an umlsterm, rheumatoiden Arthritis is an umlsterm, Boden is an umlsterm	ZfuerRheumatologie.80570025.ger.abstr_task0	Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...	[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]	[ "umlsterm" ]
Kombinationstherapie is an umlsterm, rheumatoiden Arthritis is an umlsterm, Boden is an umlsterm	ZfuerRheumatologie.80570025.ger.abstr_task1	Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please typing these entity words according to sentence: Kombinationstherapie, rheumatoiden Arthritis, Boden Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...	[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]	[ "umlsterm" ]
Kombinationstherapie, rheumatoiden Arthritis, Boden	ZfuerRheumatologie.80570025.ger.abstr_task2	Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...	[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]	[ "umlsterm" ]
translocons is a Cellular_component, endoplasmic reticulum is a Cellular_component, inner membrane is a Cellular_component, aqueous pore is a Cellular_component, membrane is a Cellular_component, membrane is a Cellular_component, translocation pore is a Cellular_component, cytosolic is a Organism_substance, membrane is a Cellular_component, translocation pore is a Cellular_component, translocon is a Cellular_component, translocon is a Cellular_component, membrane is a Cellular_component, translocon is a Cellular_component	PMID-11716301_task0	Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.	[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]	[ "Cellular_component", "Organism_substance" ]
translocons is a Cellular_component, endoplasmic reticulum is a Cellular_component, inner membrane is a Cellular_component, aqueous pore is a Cellular_component, membrane is a Cellular_component, membrane is a Cellular_component, translocation pore is a Cellular_component, cytosolic is a Organism_substance, membrane is a Cellular_component, translocation pore is a Cellular_component, translocon is a Cellular_component, translocon is a Cellular_component, membrane is a Cellular_component, translocon is a Cellular_component	PMID-11716301_task1	Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please typing these entity words according to sentence: translocons, endoplasmic reticulum, inner membrane, aqueous pore, membrane, membrane, translocation pore, cytosolic, membrane, translocation pore, translocon, translocon, membrane, translocon Options: Cellular_component, Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.	[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]	[ "Cellular_component", "Organism_substance" ]
translocons, endoplasmic reticulum, inner membrane, aqueous pore, membrane, membrane, translocation pore, cytosolic, membrane, translocation pore, translocon, translocon, membrane, translocon	PMID-11716301_task2	Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.	[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]	[ "Cellular_component", "Organism_substance" ]
Lc753 - 893 is a protein-region, II - III loop is a protein-region, domains II - III is a protein-domain, CaV1.2 α1 is a protein, GST - C2A wt is an experimental-construct, GST - C2A * mutant is an experimental-construct, Biacore AB is a brand, glutathione - S - transferase is a protein-family, GST is an experiment-tag, GST - agarose beads is a reagent	1.0alpha7.train.1355_task0	Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, brand, experimental-construct, protein-domain, experiment-tag, reagent, protein, protein-region	[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]	The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.	[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]	[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]
Lc753 - 893 is a protein-region, II - III loop is a protein-region, domains II - III is a protein-domain, CaV1.2 α1 is a protein, GST - C2A wt is an experimental-construct, GST - C2A * mutant is an experimental-construct, Biacore AB is a brand, glutathione - S - transferase is a protein-family, GST is an experiment-tag, GST - agarose beads is a reagent	1.0alpha7.train.1355_task1	Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please typing these entity words according to sentence: Lc753 - 893, II - III loop, domains II - III, CaV1.2 α1, GST - C2A wt, GST - C2A * mutant, Biacore AB, glutathione - S - transferase, GST, GST - agarose beads Options: protein-family, brand, experimental-construct, protein-domain, experiment-tag, reagent, protein, protein-region	[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]	The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.	[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]	[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]
Lc753 - 893, II - III loop, domains II - III, CaV1.2 α1, GST - C2A wt, GST - C2A * mutant, Biacore AB, glutathione - S - transferase, GST, GST - agarose beads	1.0alpha7.train.1355_task2	Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]	The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.	[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]	[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]
cardiomyopathy is an umlsterm, dilatation is an umlsterm, ventricles is an umlsterm, causes is an umlsterm, sequela is an umlsterm, myocarditis is an umlsterm, virus is an umlsterm, causes is an umlsterm, metabolic disorders is an umlsterm, adriblastintherapy is an umlsterm, cardiomyopathy is an umlsterm, congestive heart failure is an umlsterm, complications is an umlsterm, Diagnosis is an umlsterm, invasive procedures is an umlsterm, causes is an umlsterm, therapeutic is an umlsterm, Therapy is an umlsterm, digitalis is an umlsterm, diuretics is an umlsterm, anticoagulation is an umlsterm, prognosis is an umlsterm, survival is an umlsterm, survival is an umlsterm, cardiomyopathy is an umlsterm, heart transplantation is an umlsterm	MonatsschriftKinderheilkunde.71450218.eng.abstr_task0	Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .	[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]	[ "umlsterm" ]
cardiomyopathy is an umlsterm, dilatation is an umlsterm, ventricles is an umlsterm, causes is an umlsterm, sequela is an umlsterm, myocarditis is an umlsterm, virus is an umlsterm, causes is an umlsterm, metabolic disorders is an umlsterm, adriblastintherapy is an umlsterm, cardiomyopathy is an umlsterm, congestive heart failure is an umlsterm, complications is an umlsterm, Diagnosis is an umlsterm, invasive procedures is an umlsterm, causes is an umlsterm, therapeutic is an umlsterm, Therapy is an umlsterm, digitalis is an umlsterm, diuretics is an umlsterm, anticoagulation is an umlsterm, prognosis is an umlsterm, survival is an umlsterm, survival is an umlsterm, cardiomyopathy is an umlsterm, heart transplantation is an umlsterm	MonatsschriftKinderheilkunde.71450218.eng.abstr_task1	Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please typing these entity words according to sentence: cardiomyopathy, dilatation, ventricles, causes, sequela, myocarditis, virus, causes, metabolic disorders, adriblastintherapy, cardiomyopathy, congestive heart failure, complications, Diagnosis, invasive procedures, causes, therapeutic, Therapy, digitalis, diuretics, anticoagulation, prognosis, survival, survival, cardiomyopathy, heart transplantation Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .	[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]	[ "umlsterm" ]
cardiomyopathy, dilatation, ventricles, causes, sequela, myocarditis, virus, causes, metabolic disorders, adriblastintherapy, cardiomyopathy, congestive heart failure, complications, Diagnosis, invasive procedures, causes, therapeutic, Therapy, digitalis, diuretics, anticoagulation, prognosis, survival, survival, cardiomyopathy, heart transplantation	MonatsschriftKinderheilkunde.71450218.eng.abstr_task2	Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .	[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]	[ "umlsterm" ]
miss rates is a Outcome_Other, adenomas is a Outcome_Physical, colonoscopies is a Intervention_Surgical, colonoscopy is a Intervention_Surgical, 183 patients . is a Participant_Sample-size, second colonoscopy is a Intervention_Surgical, overall miss rate for adenomas is a Outcome_Physical, patients with no or one adenoma is a Participant_Condition, variation in sensitivity is a Outcome_Physical, colonoscopic technology is a Intervention_Surgical, Miss rates is a Outcome_Other	89000_task0	Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical	[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .	[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]
miss rates is a Outcome_Other, adenomas is a Outcome_Physical, colonoscopies is a Intervention_Surgical, colonoscopy is a Intervention_Surgical, 183 patients . is a Participant_Sample-size, second colonoscopy is a Intervention_Surgical, overall miss rate for adenomas is a Outcome_Physical, patients with no or one adenoma is a Participant_Condition, variation in sensitivity is a Outcome_Physical, colonoscopic technology is a Intervention_Surgical, Miss rates is a Outcome_Other	89000_task1	Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please typing these entity words according to sentence: miss rates, adenomas, colonoscopies, colonoscopy, 183 patients ., second colonoscopy, overall miss rate for adenomas, patients with no or one adenoma, variation in sensitivity, colonoscopic technology, Miss rates Options: Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical	[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .	[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]
miss rates, adenomas, colonoscopies, colonoscopy, 183 patients ., second colonoscopy, overall miss rate for adenomas, patients with no or one adenoma, variation in sensitivity, colonoscopic technology, Miss rates	89000_task2	Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .	[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]
Skeletal muscle is an umlsterm, protein is an umlsterm, critical illness is an umlsterm, injury is an umlsterm, muscle is an umlsterm, complications is an umlsterm, patient is an umlsterm, Protein is an umlsterm, turnover is an umlsterm, treatment is an umlsterm, knowledge is an umlsterm, research is an umlsterm	IntensiveMedizin.90360619.eng.abstr_task0	Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .	[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]	[ "umlsterm" ]
Skeletal muscle is an umlsterm, protein is an umlsterm, critical illness is an umlsterm, injury is an umlsterm, muscle is an umlsterm, complications is an umlsterm, patient is an umlsterm, Protein is an umlsterm, turnover is an umlsterm, treatment is an umlsterm, knowledge is an umlsterm, research is an umlsterm	IntensiveMedizin.90360619.eng.abstr_task1	Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please typing these entity words according to sentence: Skeletal muscle, protein, critical illness, injury, muscle, complications, patient, Protein, turnover, treatment, knowledge, research Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .	[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]	[ "umlsterm" ]
Skeletal muscle, protein, critical illness, injury, muscle, complications, patient, Protein, turnover, treatment, knowledge, research	IntensiveMedizin.90360619.eng.abstr_task2	Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .	[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]	[ "umlsterm" ]
cell is a Cell, cell is a Cell, cell is a Cell, tumor is a Cancer, cancer is a Cancer, pancreas is a Organ, tumor is a Cancer, tumor is a Cancer, intron 1 is a Cellular_component, tissues is a Tissue, cell is a Cell, cell is a Cell, foci is a Cell, embryonic fibroblasts is a Cell, tumor is a Cancer	PMID-15833857_task0	Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Organ, Cancer, Cellular_component, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.	[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]	[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]
cell is a Cell, cell is a Cell, cell is a Cell, tumor is a Cancer, cancer is a Cancer, pancreas is a Organ, tumor is a Cancer, tumor is a Cancer, intron 1 is a Cellular_component, tissues is a Tissue, cell is a Cell, cell is a Cell, foci is a Cell, embryonic fibroblasts is a Cell, tumor is a Cancer	PMID-15833857_task1	Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please typing these entity words according to sentence: cell, cell, cell, tumor, cancer, pancreas, tumor, tumor, intron 1, tissues, cell, cell, foci, embryonic fibroblasts, tumor Options: Tissue, Organ, Cancer, Cellular_component, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.	[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]	[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]
cell, cell, cell, tumor, cancer, pancreas, tumor, tumor, intron 1, tissues, cell, cell, foci, embryonic fibroblasts, tumor	PMID-15833857_task2	Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.	[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]	[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]
TNF is a protein, methotrexate is a compound	DS.d50_task0	Sentence: Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA).	[ "Randomised", "trials", "have", "demonstrated", "that", "the", "efficacy", "of", "anti", "-", "tumour", "necrosis", "factor", "(", "TNF", ")", "agents", "is", "significantly", "increased", "by", "concomitant", "methotrexate", "(", "MTX", ")", "in", "rheumatoid", "arthritis", "(", "RA", ")", "." ]	[ "compound", "protein" ]

rehabilitation is an umlsterm, deaf is an umlsterm, adults is an umlsterm, deaf is an umlsterm, children is an umlsterm, cochlear implants is an umlsterm, treatment is an umlsterm, deafness is an umlsterm, development is an umlsterm, devices is an umlsterm, surgical is an umlsterm, technique is an umlsterm, hearing is an umlsterm, deaf is an umlsterm, adults is an umlsterm, telephone is an umlsterm, job is an umlsterm, deaf is an umlsterm, children is an umlsterm, schools is an umlsterm, cochlear implantation is an umlsterm, hearing is an umlsterm, rehabilitation is an umlsterm, training is an umlsterm, cochlea is an umlsterm, diagnosis is an umlsterm, temporal bone is an umlsterm, computerized tomography is an umlsterm, imaging is an umlsterm, temporal bone is an umlsterm, MRI is an umlsterm, technique is an umlsterm, postoperative is an umlsterm, X - ray is an umlsterm, projection is an umlsterm, electrode is an umlsterm, cochlea is an umlsterm

DerRadiologe.70370991.eng.abstr_task0

Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .

[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]

[ "umlsterm" ]

rehabilitation is an umlsterm, deaf is an umlsterm, adults is an umlsterm, deaf is an umlsterm, children is an umlsterm, cochlear implants is an umlsterm, treatment is an umlsterm, deafness is an umlsterm, development is an umlsterm, devices is an umlsterm, surgical is an umlsterm, technique is an umlsterm, hearing is an umlsterm, deaf is an umlsterm, adults is an umlsterm, telephone is an umlsterm, job is an umlsterm, deaf is an umlsterm, children is an umlsterm, schools is an umlsterm, cochlear implantation is an umlsterm, hearing is an umlsterm, rehabilitation is an umlsterm, training is an umlsterm, cochlea is an umlsterm, diagnosis is an umlsterm, temporal bone is an umlsterm, computerized tomography is an umlsterm, imaging is an umlsterm, temporal bone is an umlsterm, MRI is an umlsterm, technique is an umlsterm, postoperative is an umlsterm, X - ray is an umlsterm, projection is an umlsterm, electrode is an umlsterm, cochlea is an umlsterm

DerRadiologe.70370991.eng.abstr_task1

Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please typing these entity words according to sentence: rehabilitation, deaf, adults, deaf, children, cochlear implants, treatment, deafness, development, devices, surgical, technique, hearing, deaf, adults, telephone, job, deaf, children, schools, cochlear implantation, hearing, rehabilitation, training, cochlea, diagnosis, temporal bone, computerized tomography, imaging, temporal bone, MRI, technique, postoperative, X - ray, projection, electrode, cochlea Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .

[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]

[ "umlsterm" ]

rehabilitation, deaf, adults, deaf, children, cochlear implants, treatment, deafness, development, devices, surgical, technique, hearing, deaf, adults, telephone, job, deaf, children, schools, cochlear implantation, hearing, rehabilitation, training, cochlea, diagnosis, temporal bone, computerized tomography, imaging, temporal bone, MRI, technique, postoperative, X - ray, projection, electrode, cochlea

DerRadiologe.70370991.eng.abstr_task2

Sentence: In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

In the last decade , the rehabilitation of postlingually deaf adults and prelingually deaf children with cochlear implants has been established as a treatment of deafness . The technological development of the implant devices and improvement of the surgical technique have led to a considerable increase of hearing performance during the last years . The postlingually deaf adults are able to use the telephone and may be integrated in their original job . Prelingually deaf children can even visit normal schools after cochlear implantation and hearing rehabilitation training . In order to preoperatively establish the state of the cochlea , radiological diagnosis of the temporal bone is necessary . High resolution computerized tomography imaging of the temporal bone with coronar and axial 1 mm slices and MRI with thin slice technique ( three dimensional , T2 weighted turbo-spinecho sequence with 0.7 mm slices ) have proved to be valuable according to our experience . Furthermore a postoperative synoptical X-ray , in a modified Chausse III projection , offers good information about the position of the implant and insertion of the stimulating electrode into the cochlea .

[ "In", "the", "last", "decade", ",", "the", "rehabilitation", "of", "postlingually", "deaf", "adults", "and", "prelingually", "deaf", "children", "with", "cochlear", "implants", "has", "been", "established", "as", "a", "treatment", "of", "deafness", ".", "The", "technological", "development", "of", "the", "implant", "devices", "and", "improvement", "of", "the", "surgical", "technique", "have", "led", "to", "a", "considerable", "increase", "of", "hearing", "performance", "during", "the", "last", "years", ".", "The", "postlingually", "deaf", "adults", "are", "able", "to", "use", "the", "telephone", "and", "may", "be", "integrated", "in", "their", "original", "job", ".", "Prelingually", "deaf", "children", "can", "even", "visit", "normal", "schools", "after", "cochlear", "implantation", "and", "hearing", "rehabilitation", "training", ".", "In", "order", "to", "preoperatively", "establish", "the", "state", "of", "the", "cochlea", ",", "radiological", "diagnosis", "of", "the", "temporal", "bone", "is", "necessary", ".", "High", "resolution", "computerized", "tomography", "imaging", "of", "the", "temporal", "bone", "with", "coronar", "and", "axial", "1", "mm", "slices", "and", "MRI", "with", "thin", "slice", "technique", "(", "three", "dimensional", ",", "T2", "weighted", "turbo", "-", "spinecho", "sequence", "with", "0.7", "mm", "slices", ")", "have", "proved", "to", "be", "valuable", "according", "to", "our", "experience", ".", "Furthermore", "a", "postoperative", "synoptical", "X", "-", "ray", ",", "in", "a", "modified", "Chausse", "III", "projection", ",", "offers", "good", "information", "about", "the", "position", "of", "the", "implant", "and", "insertion", "of", "the", "stimulating", "electrode", "into", "the", "cochlea", "." ]

[ "umlsterm" ]

transdermal glyceryl trinitrate is a Intervention_Pharmacological, failure of intravenous infusion is a Outcome_Physical, phlebitis and extravasation is a Participant_Condition, placebo patches is a Intervention_Control, Headaches is a Outcome_Physical, analgesics is a Intervention_Pharmacological

73896_task0

Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]

Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .

[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]

transdermal glyceryl trinitrate is a Intervention_Pharmacological, failure of intravenous infusion is a Outcome_Physical, phlebitis and extravasation is a Participant_Condition, placebo patches is a Intervention_Control, Headaches is a Outcome_Physical, analgesics is a Intervention_Pharmacological

73896_task1

Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please typing these entity words according to sentence: transdermal glyceryl trinitrate, failure of intravenous infusion, phlebitis and extravasation, placebo patches, Headaches, analgesics Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]

Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .

[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]

transdermal glyceryl trinitrate, failure of intravenous infusion, phlebitis and extravasation, placebo patches, Headaches, analgesics

73896_task2

Sentence: Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O" ]

Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics .

[ "Use", "of", "transdermal", "glyceryl", "trinitrate", "to", "reduce", "failure", "of", "intravenous", "infusion", "due", "to", "phlebitis", "and", "extravasation", ".", "Self", "-", "adhesive", "patches", "which", "release", "glyceryl", "trinitrate", "at", "a", "slow", "continuous", "rate", "or", "placebo", "patches", "were", "applied", "to", "the", "skin", "of", "patients", "distal", "to", "intravenous", "infusion", "sites", "in", "a", "double", "-", "blind", "manner", ".", "The", "frequency", "of", "infusion", "failure", "was", "three", "times", "lower", "with", "the", "glyceryl", "trinitrate", "than", "with", "placebo", "patches", ".", "The", "decrease", "was", "of", "similar", "magnitude", "whether", "failure", "was", "due", "to", "extravasation", "or", "phlebitis", ".", "Headaches", "were", "more", "common", "in", "patients", "with", "active", "patches", "but", "were", "relieved", "by", "simple", "analgesics", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Intervention_Control" ]

tumor necrosis factor - alpha is a Protein, TNF - alpha is a Protein, interleukin-1 beta is a Protein, IL-1 beta is a Protein, vascular cell adhesion molecule-1 is a Protein, VCAM-1 is a Protein, CD106 is a Protein, E - selectin is a Protein, ELAM-1 is a Protein, CD62E is a Protein, intercellular adhesion molecule-1 is a Protein, ICAM-1 is a Protein, CD54 is a Protein, VCAM-1 is a Protein, E - selectin is a Protein, TNF - alpha is a Protein, IL-1 beta is a Protein, TNF - alpha is a Protein

762_task0

Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.

[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]

[ "Protein" ]

tumor necrosis factor - alpha is a Protein, TNF - alpha is a Protein, interleukin-1 beta is a Protein, IL-1 beta is a Protein, vascular cell adhesion molecule-1 is a Protein, VCAM-1 is a Protein, CD106 is a Protein, E - selectin is a Protein, ELAM-1 is a Protein, CD62E is a Protein, intercellular adhesion molecule-1 is a Protein, ICAM-1 is a Protein, CD54 is a Protein, VCAM-1 is a Protein, E - selectin is a Protein, TNF - alpha is a Protein, IL-1 beta is a Protein, TNF - alpha is a Protein

762_task1

Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please typing these entity words according to sentence: tumor necrosis factor - alpha, TNF - alpha, interleukin-1 beta, IL-1 beta, vascular cell adhesion molecule-1, VCAM-1, CD106, E - selectin, ELAM-1, CD62E, intercellular adhesion molecule-1, ICAM-1, CD54, VCAM-1, E - selectin, TNF - alpha, IL-1 beta, TNF - alpha Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.

[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]

[ "Protein" ]

tumor necrosis factor - alpha, TNF - alpha, interleukin-1 beta, IL-1 beta, vascular cell adhesion molecule-1, VCAM-1, CD106, E - selectin, ELAM-1, CD62E, intercellular adhesion molecule-1, ICAM-1, CD54, VCAM-1, E - selectin, TNF - alpha, IL-1 beta, TNF - alpha

762_task2

Sentence: alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization. The adherence of monocytes to activated endothelium is an early event in atherogenesis. Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC). Endothelial cells were treated with TCP, alpha-tocopherol acetate (TCP acetate), or alpha-tocopheryl succinate (TCP succinate) before stimulation with tumor necrosis factor-alpha (TNF-alpha; 10 U/ml, 6 h) or interleukin-1 beta (IL-1 beta; 10 U/ml, 6 h). Cytokine-stimulated cell surface expression of vascular cell adhesion molecule-1 (VCAM-1, CD106) and E-selectin (ELAM-1, CD62E), but not of intercellular adhesion molecule-1 (ICAM-1, CD54), was time- and dose-dependently inhibited by TCP succinate but not by TCP or TCP acetate. TCP succinate (200 microM, 24 h) reduced TNF-induced VCAM-1 and E-selectin expression from a specific mean fluorescence intensity of 151 +/- 28 to 12 +/- 4 channels and from 225 +/- 38 to 79 +/- 21 channels, respectively. Succinate alone had no effect. Decreased adhesion molecule expression was associated with a reduction of monocytic cell adhesion. TCP succinate (20 microM, 72 h), but not TCP (200 microM, 72 h), reduced U-937 cell adhesion to TNF-alpha-stimulated (10 U/ml, 6 h) HUVEC by 30% (P < 0.025) and to IL-1 beta-stimulated HUVEC by 56% (P < 0.010). Electrophoretic mobility-shift assays of HUVEC nuclear proteins revealed a decrease in TNF-alpha-stimulated nuclear factor-kappa B (NF-kappa B) activation after pretreatment of HUVEC with TCP succinate but not with TCP, TCP acetate, or succinate alone. In conclusion, we demonstrate that the vitamin E derivative TCP succinate prevents monocytic cell adhesion to cytokine-stimulated endothelial cells by inhibiting the activation of NF-kappa B, further emphasizing the antiatherosclerotic potential of lipid soluble antioxidants.

[ "alpha", "-", "Tocopheryl", "succinate", "inhibits", "monocytic", "cell", "adhesion", "to", "endothelial", "cells", "by", "suppressing", "NF", "-", "kappa", "B", "mobilization", ".", "\n", "The", "adherence", "of", "monocytes", "to", "activated", "endothelium", "is", "an", "early", "event", "in", "atherogenesis", ".", "Because", "antioxidants", "have", "been", "considered", "to", "be", "of", "antiatherosclerotic", "potential", ",", "we", "investigated", "the", "effects", "of", "alpha", "-", "tocopherol", "(", "TCP", ")", "and", "its", "acetate", "and", "succinate", "esters", "on", "monocyte", "adhesion", "to", "cytokine", "-", "stimulated", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVEC", ")", ".", "Endothelial", "cells", "were", "treated", "with", "TCP", ",", "alpha", "-", "tocopherol", "acetate", "(", "TCP", "acetate", ")", ",", "or", "alpha", "-", "tocopheryl", "succinate", "(", "TCP", "succinate", ")", "before", "stimulation", "with", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ";", "10", "U", "/", "ml", ",", "6", "h", ")", "or", "interleukin-1", "beta", "(", "IL-1", "beta", ";", "10", "U", "/", "ml", ",", "6", "h", ")", ".", "Cytokine", "-", "stimulated", "cell", "surface", "expression", "of", "vascular", "cell", "adhesion", "molecule-1", "(", "VCAM-1", ",", "CD106", ")", "and", "E", "-", "selectin", "(", "ELAM-1", ",", "CD62E", ")", ",", "but", "not", "of", "intercellular", "adhesion", "molecule-1", "(", "ICAM-1", ",", "CD54", ")", ",", "was", "time-", "and", "dose", "-", "dependently", "inhibited", "by", "TCP", "succinate", "but", "not", "by", "TCP", "or", "TCP", "acetate", ".", "TCP", "succinate", "(", "200", "microM", ",", "24", "h", ")", "reduced", "TNF", "-", "induced", "VCAM-1", "and", "E", "-", "selectin", "expression", "from", "a", "specific", "mean", "fluorescence", "intensity", "of", "151", "+", "/-", "28", "to", "12", "+", "/-", "4", "channels", "and", "from", "225", "+", "/-", "38", "to", "79", "+", "/-", "21", "channels", ",", "respectively", ".", "Succinate", "alone", "had", "no", "effect", ".", "Decreased", "adhesion", "molecule", "expression", "was", "associated", "with", "a", "reduction", "of", "monocytic", "cell", "adhesion", ".", "TCP", "succinate", "(", "20", "microM", ",", "72", "h", ")", ",", "but", "not", "TCP", "(", "200", "microM", ",", "72", "h", ")", ",", "reduced", "U-937", "cell", "adhesion", "to", "TNF", "-", "alpha", "-", "stimulated", "(", "10", "U", "/", "ml", ",", "6", "h", ")", "HUVEC", "by", "30", "%", "(", "P", "<", "0.025", ")", "and", "to", "IL-1", "beta", "-", "stimulated", "HUVEC", "by", "56", "%", "(", "P", "<", "0.010", ")", ".", "Electrophoretic", "mobility", "-", "shift", "assays", "of", "HUVEC", "nuclear", "proteins", "revealed", "a", "decrease", "in", "TNF", "-", "alpha", "-", "stimulated", "nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", "activation", "after", "pretreatment", "of", "HUVEC", "with", "TCP", "succinate", "but", "not", "with", "TCP", ",", "TCP", "acetate", ",", "or", "succinate", "alone", ".", "In", "conclusion", ",", "we", "demonstrate", "that", "the", "vitamin", "E", "derivative", "TCP", "succinate", "prevents", "monocytic", "cell", "adhesion", "to", "cytokine", "-", "stimulated", "endothelial", "cells", "by", "inhibiting", "the", "activation", "of", "NF", "-", "kappa", "B", ",", "further", "emphasizing", "the", "antiatherosclerotic", "potential", "of", "lipid", "soluble", "antioxidants", "." ]

[ "Protein" ]

Patienten is an umlsterm, Spaetlaehmung is an umlsterm, elektroneurographisch is an umlsterm

DerUnfallchirurg.60990784.ger.abstr_task0

Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .

[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Spaetlaehmung is an umlsterm, elektroneurographisch is an umlsterm

DerUnfallchirurg.60990784.ger.abstr_task1

Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please typing these entity words according to sentence: Patienten, Spaetlaehmung, elektroneurographisch Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .

[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]

[ "umlsterm" ]

Patienten, Spaetlaehmung, elektroneurographisch

DerUnfallchirurg.60990784.ger.abstr_task2

Sentence: 7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

7 Patienten bei denen wegen Spaetlaehmung des N. ulnaris vor 10 - 30 Jahren , eine intermuskulaere Nervenverlagerung vorgenommen worden war , wurden klinisch und elektroneurographisch nachuntersucht . Die Untersuchung zeigt , dass nach guten Fruehergebnissen durch die Verlagerungen keine Spaetschaeden des Nerven zu erwarten sind .

[ "7", "Patienten", "bei", "denen", "wegen", "Spaetlaehmung", "des", "N.", "ulnaris", "vor", "10", "-", "30", "Jahren", ",", "eine", "intermuskulaere", "Nervenverlagerung", "vorgenommen", "worden", "war", ",", "wurden", "klinisch", "und", "elektroneurographisch", "nachuntersucht", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "nach", "guten", "Fruehergebnissen", "durch", "die", "Verlagerungen", "keine", "Spaetschaeden", "des", "Nerven", "zu", "erwarten", "sind", "." ]

[ "umlsterm" ]

HP1 chromodomain is a protein-domain, histone H3 is a protein-family, lysine 9 is an amino-acid, methyllysine is an amino-acid

1.0alpha7.train.881_task0

Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: amino-acid, protein-domain, protein-family

[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).

[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]

[ "protein-domain", "amino-acid", "protein-family", "protein" ]

HP1 chromodomain is a protein-domain, histone H3 is a protein-family, lysine 9 is an amino-acid, methyllysine is an amino-acid

1.0alpha7.train.881_task1

Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please typing these entity words according to sentence: HP1 chromodomain, histone H3, lysine 9, methyllysine Options: amino-acid, protein-domain, protein-family

[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).

[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]

[ "protein-domain", "amino-acid", "protein-family", "protein" ]

HP1 chromodomain, histone H3, lysine 9, methyllysine

1.0alpha7.train.881_task2

Sentence: The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "B-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "B-amino-acid", "I-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The structure of the HP1 chromodomain bound to histone H3 di- or trimethylated at lysine 9 shows that either peptide fits in a groove and lodges the methyllysine in a hydrophobic pocket (Nielsen et al., 2002 ; Jacobs and Khorasanizadeh, 2002 ).

[ "The", "structure", "of", "the", " ", "HP1", "chromodomain", "bound", "to", "histone", "H3", " ", "di-", "or", "trimethylated", "at", " ", "lysine", "9", "shows", "that", "either", "peptide", "fits", "in", "a", "groove", "and", "lodges", "the", "methyllysine", "in", "a", "hydrophobic", "pocket", "(", "Nielsen", "et", "al", ".", ",", "2002", " ", ";", "Jacobs", "and", "Khorasanizadeh", ",", "2002", " ", ")", "." ]

[ "protein-domain", "amino-acid", "protein-family", "protein" ]

CLR16.2 is a Protein, NBD / LRR family is a Protein, T cell is a Cell, function is a Function, mammalian is a Eukaryote, CATERPILLER ( NOD , NALP , PAN ) family is a Protein, proteins is a Protein, NBD - LRR superfamily is a Protein, plant is a Eukaryote, disease resistance ( R ) proteins is a Protein, function is a Function, cloning is a ExperimentalMethod, CATERPILLER gene is a Gene, CLR16.2 is a Gene, human is a Eukaryote, chromosome 16 is a Chromosome, protein is a Protein, gene is a Gene, NBD - LRR configuration is a Protein, CLR16.2 is a Gene, T lymphocytes is a Cell, Cellular is a Cell, CLR16.2 is a Protein, cytoplasmic is a CellComponent, protein is a Protein, CLR16.2 is a Protein, anti - CD3 is a Protein, anti - CD28 is a Protein, primary T lymphocytes is a Cell, T cell is a Cell, CLR16.2 is a Protein, NF - kappaB is a Protein, NFAT is a Protein, AP-1 is a Protein, reporter gene constructs is a ReporterGeneConstruction, T cell is a AP2EREBPRelatedDomain, anti - CD3 is a Protein, anti - CD28 is a Protein, antibodies is a Protein, PMA is a Protein, ionomycin is a Protein, T cell is a Cell, CLR16.2 is a Protein, transcripts is a Transcript, IL-2 is a Protein, CD25 proteins is a Protein, T cell is a Cell, IkappaBalpha is a AP2EREBPRelatedDomain, CLR16.2 is a Protein, T cell is a Cell, TCR is a Protein, co - stimulatory molecules is a MolecularEntity, T cell is a Cell, cellular is a Cell

81_task0

Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ReporterGeneConstruction, Function, ExperimentalMethod, CellComponent, Chromosome, Gene, AP2EREBPRelatedDomain, Transcript, MolecularEntity, Eukaryote, Protein, Cell

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]

CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.

[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]

[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]

CLR16.2 is a Protein, NBD / LRR family is a Protein, T cell is a Cell, function is a Function, mammalian is a Eukaryote, CATERPILLER ( NOD , NALP , PAN ) family is a Protein, proteins is a Protein, NBD - LRR superfamily is a Protein, plant is a Eukaryote, disease resistance ( R ) proteins is a Protein, function is a Function, cloning is a ExperimentalMethod, CATERPILLER gene is a Gene, CLR16.2 is a Gene, human is a Eukaryote, chromosome 16 is a Chromosome, protein is a Protein, gene is a Gene, NBD - LRR configuration is a Protein, CLR16.2 is a Gene, T lymphocytes is a Cell, Cellular is a Cell, CLR16.2 is a Protein, cytoplasmic is a CellComponent, protein is a Protein, CLR16.2 is a Protein, anti - CD3 is a Protein, anti - CD28 is a Protein, primary T lymphocytes is a Cell, T cell is a Cell, CLR16.2 is a Protein, NF - kappaB is a Protein, NFAT is a Protein, AP-1 is a Protein, reporter gene constructs is a ReporterGeneConstruction, T cell is a AP2EREBPRelatedDomain, anti - CD3 is a Protein, anti - CD28 is a Protein, antibodies is a Protein, PMA is a Protein, ionomycin is a Protein, T cell is a Cell, CLR16.2 is a Protein, transcripts is a Transcript, IL-2 is a Protein, CD25 proteins is a Protein, T cell is a Cell, IkappaBalpha is a AP2EREBPRelatedDomain, CLR16.2 is a Protein, T cell is a Cell, TCR is a Protein, co - stimulatory molecules is a MolecularEntity, T cell is a Cell, cellular is a Cell

81_task1

Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please typing these entity words according to sentence: CLR16.2, NBD / LRR family, T cell, function, mammalian, CATERPILLER ( NOD , NALP , PAN ) family, proteins, NBD - LRR superfamily, plant, disease resistance ( R ) proteins, function, cloning, CATERPILLER gene, CLR16.2, human, chromosome 16, protein, gene, NBD - LRR configuration, CLR16.2, T lymphocytes, Cellular, CLR16.2, cytoplasmic, protein, CLR16.2, anti - CD3, anti - CD28, primary T lymphocytes, T cell, CLR16.2, NF - kappaB, NFAT, AP-1, reporter gene constructs, T cell, anti - CD3, anti - CD28, antibodies, PMA, ionomycin, T cell, CLR16.2, transcripts, IL-2, CD25 proteins, T cell, IkappaBalpha, CLR16.2, T cell, TCR, co - stimulatory molecules, T cell, cellular Options: ReporterGeneConstruction, Function, ExperimentalMethod, CellComponent, Chromosome, Gene, AP2EREBPRelatedDomain, Transcript, MolecularEntity, Eukaryote, Protein, Cell

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]

CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.

[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]

[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]

CLR16.2, NBD / LRR family, T cell, function, mammalian, CATERPILLER ( NOD , NALP , PAN ) family, proteins, NBD - LRR superfamily, plant, disease resistance ( R ) proteins, function, cloning, CATERPILLER gene, CLR16.2, human, chromosome 16, protein, gene, NBD - LRR configuration, CLR16.2, T lymphocytes, Cellular, CLR16.2, cytoplasmic, protein, CLR16.2, anti - CD3, anti - CD28, primary T lymphocytes, T cell, CLR16.2, NF - kappaB, NFAT, AP-1, reporter gene constructs, T cell, anti - CD3, anti - CD28, antibodies, PMA, ionomycin, T cell, CLR16.2, transcripts, IL-2, CD25 proteins, T cell, IkappaBalpha, CLR16.2, T cell, TCR, co - stimulatory molecules, T cell, cellular

81_task2

Sentence: CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Cell", "I-Cell", "B-Function", "O", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "O", "O", "O", "O", "O", "B-ExperimentalMethod", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Chromosome", "I-Chromosome", "O", "O", "B-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-CellComponent", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "B-ReporterGeneConstruction", "I-ReporterGeneConstruction", "I-ReporterGeneConstruction", "O", "O", "O", "B-AP2EREBPRelatedDomain", "I-AP2EREBPRelatedDomain", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-AP2EREBPRelatedDomain", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "O", "B-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "I-MolecularEntity", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]

CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappaB, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of IkappaBalpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.

[ "CATERPILLER", "16.2", "(", "CLR16.2", ")", ",", "a", "novel", "NBD", "/", "LRR", "family", "member", "that", "negatively", "regulates", "T", "cell", "function", ".", "The", "newly", "discovered", "mammalian", "CATERPILLER", "(", "NOD", ",", "NALP", ",", "PAN", ")", "family", "of", "proteins", "share", "similarities", "with", "the", "NBD", "-", "LRR", "superfamily", "of", "plant", "disease", "resistance", "(", "R", ")", "proteins", "and", "are", "predicted", "to", "mediate", "important", "immune", "regulatory", "function", ".", "This", "report", "describes", "the", "first", "cloning", "and", "characterization", "of", "a", "novel", "CATERPILLER", "gene", ",", "CLR16.2", "that", "is", "located", "on", "human", "chromosome", "16", ".", "The", "protein", "encoded", "by", "this", "gene", "has", "a", "typical", "NBD", "-", "LRR", "configuration", ".", "Analysis", "of", "CLR16.2", "suggests", "the", "highest", "expression", "among", "T", "lymphocytes", ".", "Cellular", "localization", "studies", "of", "CLR16.2", "revealed", "that", "it", "is", "a", "cytoplasmic", "protein", ".", "Querying", "microarray", "studies", "in", "the", "public", "data", "base", "showed", "that", "CLR16.2", "was", "significantly", "(", ">", "90", "%", ")", "down", "-", "regulated", "6", "h", "after", "anti", "-", "CD3", "and", "anti", "-", "CD28", "stimulation", "of", "primary", "T", "lymphocytes", ".", "Its", "reduction", "upon", "T", "cell", "stimulation", "is", "consistent", "with", "a", "potential", "negative", "regulatory", "role", ".", "Indeed", "CLR16.2", "decreased", "NF", "-", "kappaB", ",", "NFAT", ",", "and", "AP-1", "induction", "of", "reporter", "gene", "constructs", "in", "response", "to", "T", "cell", "activation", "by", "anti", "-", "CD3", "and", "anti", "-", "CD28", "antibodies", "or", "PMA", "and", "ionomycin", ".", "Following", "T", "cell", "stimulation", ",", "the", "presence", "of", "CLR16.2", "reduced", "the", "levels", "of", "the", "endogenous", "transcripts", "for", "the", "IL-2", "and", "CD25", "proteins", "that", "are", "central", "in", "maintaining", "T", "cell", "activation", "and", "preventing", "T", "cell", "anergy", ".", "This", "reduction", "was", "accompanied", "by", "a", "delay", "of", "IkappaBalpha", "degradation", ".", "We", "propose", "that", "CLR16.2", "serves", "to", "attenuate", "T", "cell", "activation", "via", "TCR", "and", "co", "-", "stimulatory", "molecules", ",", "and", "its", "reduction", "during", "T", "cell", "stimulation", "allows", "the", "ensuing", "cellular", "activation", ".", "\n" ]

[ "Protein", "ReporterGeneConstruction", "MolecularEntity", "Cell", "Gene", "Chromosome", "AP2EREBPRelatedDomain", "CellComponent", "Transcript", "Eukaryote", "Function", "ExperimentalMethod" ]

Pyk2 is a protein, Grb2 is a protein, Shc is a protein, ERK2 is a protein

1.0alpha7.train.647_task0

Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.

[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]

[ "protein", "cell" ]

Pyk2 is a protein, Grb2 is a protein, Shc is a protein, ERK2 is a protein

1.0alpha7.train.647_task1

Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please typing these entity words according to sentence: Pyk2, Grb2, Shc, ERK2 Options: protein

[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.

[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]

[ "protein", "cell" ]

Pyk2, Grb2, Shc, ERK2

1.0alpha7.train.647_task2

Sentence: Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells. Instructions: please extract entity words from the input sentence

[ "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Increased Pyk2 tyrosine phosphorylation paralleled the time-course of Grb2 binding to Shc and activation of ERK2 in FAK- cells.

[ "Increased", "Pyk2", "tyrosine", "phosphorylation", "paralleled", "the", "time", "-", "course", "of", " ", "Grb2", "binding", "to", " ", "Shc", "and", "activation", "of", " ", "ERK2", "in", " ", "FAK-", "cells", "." ]

[ "protein", "cell" ]

Cardiolipin is a CHEMICAL

23172229_task0

Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.

[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Cardiolipin is a CHEMICAL

23172229_task1

Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please typing these entity words according to sentence: Cardiolipin Options: CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.

[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Cardiolipin

23172229_task2

Sentence: Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.

[ "Cardiolipin", "-", "dependent", "reconstitution", "of", "respiratory", "supercomplexes", "from", "purified", "Saccharomyces", "cerevisiae", "complexes", "III", "and", "IV", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Monocytic differentiation is an other_name, HL-60 promyelocytic leukemia cells is a cell_line

54876_task0

Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, other_name

[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]

Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.

[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]

[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]

Monocytic differentiation is an other_name, HL-60 promyelocytic leukemia cells is a cell_line

54876_task1

Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please typing these entity words according to sentence: Monocytic differentiation, HL-60 promyelocytic leukemia cells Options: cell_line, other_name

[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]

Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.

[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]

[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]

Monocytic differentiation, HL-60 promyelocytic leukemia cells

54876_task2

Sentence: Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "O", "O", "O", "O", "O" ]

Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL.

[ "Monocytic", "differentiation", "of", "HL-60", "promyelocytic", "leukemia", "cells", "correlates", "with", "the", "induction", "of", "Bcl", "-", "xL." ]

[ "cell_line", "other_name", "cell_type", "other_organic_compound", "protein_family_or_group", "protein_molecule" ]

Silvia is a NOMBRE_SUJETO_ASISTENCIA, Pinal Guzman is a NOMBRE_SUJETO_ASISTENCIA, 8034756 is a ID_SUJETO_ASISTENCIA, 34 856758 37 is a ID_ASEGURAMIENTO, C/ Aviacion Española , 13 is a CALLE, Barañain is a TERRITORIO, 31010 is a TERRITORIO, 04/08/1981 is a FECHAS, España is a PAIS, 36 años is a EDAD_SUJETO_ASISTENCIA, 28/05/2018 is a FECHAS, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, 31 31 25230 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 36 años is a EDAD_SUJETO_ASISTENCIA, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, Clínica Hospital Virgen del Camino is a HOSPITAL, Ronda Cendea de Zizur , 58 - 2ºC is a CALLE, 31010 is a TERRITORIO, Barañain is a TERRITORIO, Navarra is a TERRITORIO, drarociomilena@hotmail.com is a CORREO_ELECTRONICO

410_task0

Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Silvia is a NOMBRE_SUJETO_ASISTENCIA, Pinal Guzman is a NOMBRE_SUJETO_ASISTENCIA, 8034756 is a ID_SUJETO_ASISTENCIA, 34 856758 37 is a ID_ASEGURAMIENTO, C/ Aviacion Española , 13 is a CALLE, Barañain is a TERRITORIO, 31010 is a TERRITORIO, 04/08/1981 is a FECHAS, España is a PAIS, 36 años is a EDAD_SUJETO_ASISTENCIA, 28/05/2018 is a FECHAS, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, 31 31 25230 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 36 años is a EDAD_SUJETO_ASISTENCIA, Rocío Milena Pabón Meneses is a NOMBRE_PERSONAL_SANITARIO, Clínica Hospital Virgen del Camino is a HOSPITAL, Ronda Cendea de Zizur , 58 - 2ºC is a CALLE, 31010 is a TERRITORIO, Barañain is a TERRITORIO, Navarra is a TERRITORIO, drarociomilena@hotmail.com is a CORREO_ELECTRONICO

410_task1

Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please typing these entity words according to sentence: Silvia, Pinal Guzman, 8034756, 34 856758 37, C/ Aviacion Española , 13, Barañain, 31010, 04/08/1981, España, 36 años, 28/05/2018, Rocío Milena Pabón Meneses, 31 31 25230, Mujer, 36 años, Rocío Milena Pabón Meneses, Clínica Hospital Virgen del Camino, Ronda Cendea de Zizur , 58 - 2ºC, 31010, Barañain, Navarra, drarociomilena@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Silvia, Pinal Guzman, 8034756, 34 856758 37, C/ Aviacion Española , 13, Barañain, 31010, 04/08/1981, España, 36 años, 28/05/2018, Rocío Milena Pabón Meneses, 31 31 25230, Mujer, 36 años, Rocío Milena Pabón Meneses, Clínica Hospital Virgen del Camino, Ronda Cendea de Zizur , 58 - 2ºC, 31010, Barañain, Navarra, drarociomilena@hotmail.com

410_task2

Sentence: Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Silvia. Apellidos: Pinal Guzman. NHC: 8034756 . NASS: 34 856758 37. Domicilio: C/ Aviacion Española, 13. Localidad/ Provincia: Barañain. CP: 31010. Datos asistenciales. Fecha de nacimiento: 04/08/1981. País: España. Edad: 36 años Sexo: M. Fecha de Ingreso: 28/05/2018. Médico: Rocío Milena Pabón Meneses NºCol: 31 31 25230. Informe clínico del paciente: Mujer de 36 años, sin antecedentes, que inicia con parestesias en dedo pulgar de la mano derecha seguidas, 2 días después, de debilidad para el movimiento de pinza. Dos días más tarde, aparece paresia para la dorsiflexión del pie izquierdo y parestesias dolorosas en el dorso del mismo. Fue ingresada al cabo de una semana del inicio la semana de evolución, observandose paresia grado 3 en la escala del Medical Research Council (MRC) del oponente y del abductor corto del pulgar (ACP) derechos y grado 4 MRC de los músculos dependientes del ciático poplíteo externo (CPE) izquierdo junto con hipoestesia táctil y dolorosa en primer y segundo dedos de la mano derecha y en dorso del pie izquierdo. Mostraba un buen estado general sin fiebre, lesiones cutáneas ni adenopatías. Cinco días después de su ingreso aparecen nuevas alteraciones neurológicas consistentes en paresia grado 3 MRC de deltoides y de tríceps braquial izquierdo y parestesias en cara externa del brazo izquierdo y ambas pantorrillas. Los estudios complementarios realizados incluyeron velocidad de sedimentación globular (VSG), hemograma, bioquímica elemental de sangre y orina, estudio de liquido cefalorraquídeo (LCR), estudio de coagulación que incluyó plaquetas, volumen plaquetar medio, tiempo de protrombina, Ratio Internacional Normalizada (INR) y fibrinógeno, proteinograma, inmunoglobulinas, fracciones C3 y C4 del complemento, crioglobulinas, anticuerpos antinucleares (ANA), anticuerpos anti citoplasma del neutrófilo (ANCA), anticuerpos anticardiolipina IgG e IgM y antigangliósidos GM1 y GD1b, factor reumatoide, serología a lúes (RPR), Borrelia burgdorferi y hepatitis B y C, Mantoux, electrocardiograma (ECG), radiografía de tórax, resonancia magnetica (RM) cerebral, torácica y abdominal. Los hallazgos de estas exploraciones resultaron dentro del rango de la normalidad. Durante el ingreso se realizan dos estudios neurofisiológicos que se detallan en la tabla 1. El primero realizado a los 9 días del inicio de los síntomas, destacó la ausencia de potencial motor (PM) del CPE izquierdo y una reducción de la amplitud del PM del mediano derecho con estímulos en muñeca, codo y axila respecto a la del obtenido con estimulación palmar. El electromiograma (EMG) del ACP derecho mostraba un patrón de máximo esfuerzo simple con escasos potenciales de unidad motora (PUMs) de características normales y sin actividad espontánea. En el tibial anterior (TA) izquierdo no se registro actividad espontánea ni voluntaria. En el segundo estudio realizado a los 15 días de evolución, se objetivaron cambios en la conducción sensitiva de varios nervios, que previamente no habían mostrado alteraciones. Éstos incluyeron, reducción de la amplitud del potencial sensitivo del nervio peroneal superficial izquierdo, ausencia de respuestas sensitivas en los nervios surales y en el mediano derecho al estímular en tercer dedo y disminución de la amplitud de los obtenidos desde primer y segundo dedos. Como en el primer estudio, no se obtuvo PM del CPE izquierdo. La amplitud de los PMs del mediano derecho estaba reducida, incluyendo la correspondiente a la estimulación en la palma, que había disminuido respecto a la del estudio previo. En el EMG se registró actividad espontánea en forma de fibrilaciones y ondas positivas, abundantes en el ACP derecho y escasas en TA y pedio izquierdos. Como en el estudio anterior, el reflejo H y las ondas F de cubitales, tibiales posteriores, mediano izquierdo y CPE derecho fueron normales y no se observaron bloqueos proximales de la conducción motora en el mediano izquierdo y en ambos cubitales, obteniéndose valores normales hasta punto de Erb. Se realizó una biopsia del nervio sural izquierdo, que mostró degeneración axonal e infiltrado inflamatorio perivascular compatible con infarto por vasculitis. Se instauró tratamiento con 60 mg/día de prednisona, con mejoría subjetiva de la debilidad muscular y de las parestesias dolorosas. Posteriormente se redujo gradualmente la dosis de prednisona. A los 9 meses, 45 mg a días alternos, mejoría de parestesias en las extremidades inferiores y de fuerza proximal en la extremidad superior izquierda. Persistía déficit sensitivomotor en la mano derecha y paresia marcada en territorio del CPE izquierdo. Un tercer estudio neurofisiológico realizado a los 9 meses no mostro cambios significativos respecto al anterior, excepto la reaparición del potencial sensitivo de baja amplitud en el nervio sural derecho. En el EMG persistía moderada actividad espontánea en ACP derecho y TA izquierdo, con patrones de máximo esfuerzo marcadamente deficitarios y PUMs con signos de reinervación activa, irregulares (polifásicos y politurns) e inestables. Remitido por: Rocío Milena Pabón Meneses Servicio de Neurofisiología Clínica Hospital Virgen del Camino Ronda Cendea de Zizur, 58-2ºC 31010 Barañain. Navarra Tfno.+34679802102 E-mail: drarociomilena@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Silvia", ".", "\n", "Apellidos", ":", "Pinal", "Guzman", ".", "\n", "NHC", ":", "8034756", ".", "\n", "NASS", ":", "34", "856758", "37", ".", "\n", "Domicilio", ":", "C/", "Aviacion", "Española", ",", "13", ".", "\n", "Localidad/", "Provincia", ":", "Barañain", ".", "\n", "CP", ":", "31010", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "04/08/1981", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "36", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "28/05/2018", ".", "\n", "Médico", ":", "Rocío", "Milena", "Pabón", "Meneses", "NºCol", ":", "31", "31", "25230", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "36", "años", ",", "sin", "antecedentes", ",", "que", "inicia", "con", "parestesias", "en", "dedo", "pulgar", "de", "la", "mano", "derecha", "seguidas", ",", "2", "días", "después", ",", "de", "debilidad", "para", "el", "movimiento", "de", "pinza", ".", "Dos", "días", "más", "tarde", ",", "aparece", "paresia", "para", "la", "dorsiflexión", "del", "pie", "izquierdo", "y", "parestesias", "dolorosas", "en", "el", "dorso", "del", "mismo", ".", "Fue", "ingresada", "al", "cabo", "de", "una", "semana", "del", "inicio", "la", "semana", "de", "evolución", ",", "observandose", "paresia", "grado", "3", "en", "la", "escala", "del", "Medical", "Research", "Council", "(", "MRC", ")", "del", "oponente", "y", "del", "abductor", "corto", "del", "pulgar", "(", "ACP", ")", "derechos", "y", "grado", "4", "MRC", "de", "los", "músculos", "dependientes", "del", "ciático", "poplíteo", "externo", "(", "CPE", ")", "izquierdo", "junto", "con", "hipoestesia", "táctil", "y", "dolorosa", "en", "primer", "y", "segundo", "dedos", "de", "la", "mano", "derecha", "y", "en", "dorso", "del", "pie", "izquierdo", ".", "Mostraba", "un", "buen", "estado", "general", "sin", "fiebre", ",", "lesiones", "cutáneas", "ni", "adenopatías", ".", "Cinco", "días", "después", "de", "su", "ingreso", "aparecen", "nuevas", "alteraciones", "neurológicas", "consistentes", "en", "paresia", "grado", "3", "MRC", "de", "deltoides", "y", "de", "tríceps", "braquial", "izquierdo", "y", "parestesias", "en", "cara", "externa", "del", "brazo", "izquierdo", "y", "ambas", "pantorrillas", ".", "\n", "Los", "estudios", "complementarios", "realizados", "incluyeron", "velocidad", "de", "sedimentación", "globular", "(", "VSG", ")", ",", "hemograma", ",", "bioquímica", "elemental", "de", "sangre", "y", "orina", ",", "estudio", "de", "liquido", "cefalorraquídeo", "(", "LCR", ")", ",", "estudio", "de", "coagulación", "que", "incluyó", "plaquetas", ",", "volumen", "plaquetar", "medio", ",", "tiempo", "de", "protrombina", ",", "Ratio", "Internacional", "Normalizada", "(", "INR", ")", "y", "fibrinógeno", ",", "proteinograma", ",", "inmunoglobulinas", ",", "fracciones", "C3", "y", "C4", "del", "complemento", ",", "crioglobulinas", ",", "anticuerpos", "antinucleares", "(", "ANA", ")", ",", "anticuerpos", "anti", "citoplasma", "del", "neutrófilo", "(", "ANCA", ")", ",", "anticuerpos", "anticardiolipina", "IgG", "e", "IgM", "y", "antigangliósidos", "GM1", "y", "GD1b", ",", "factor", "reumatoide", ",", "serología", "a", "lúes", "(", "RPR", ")", ",", "Borrelia", "burgdorferi", "y", "hepatitis", "B", "y", "C", ",", "Mantoux", ",", "electrocardiograma", "(", "ECG", ")", ",", "radiografía", "de", "tórax", ",", "resonancia", "magnetica", "(", "RM", ")", "cerebral", ",", "torácica", "y", "abdominal", ".", "Los", "hallazgos", "de", "estas", "exploraciones", "resultaron", "dentro", "del", "rango", "de", "la", "normalidad", ".", "\n", "Durante", "el", "ingreso", "se", "realizan", "dos", "estudios", "neurofisiológicos", "que", "se", "detallan", "en", "la", "tabla", "1", ".", "El", "primero", "realizado", "a", "los", "9", "días", "del", "inicio", "de", "los", "síntomas", ",", "destacó", "la", "ausencia", "de", "potencial", "motor", "(", "PM", ")", "del", "CPE", "izquierdo", "y", "una", "reducción", "de", "la", "amplitud", "del", "PM", "del", "mediano", "derecho", "con", "estímulos", "en", "muñeca", ",", "codo", "y", "axila", "respecto", "a", "la", "del", "obtenido", "con", "estimulación", "palmar", ".", "El", "electromiograma", "(", "EMG", ")", "del", "ACP", "derecho", "mostraba", "un", "patrón", "de", "máximo", "esfuerzo", "simple", "con", "escasos", "potenciales", "de", "unidad", "motora", "(", "PUMs", ")", "de", "características", "normales", "y", "sin", "actividad", "espontánea", ".", "En", "el", "tibial", "anterior", "(", "TA", ")", "izquierdo", "no", "se", "registro", "actividad", "espontánea", "ni", "voluntaria", ".", "En", "el", "segundo", "estudio", "realizado", "a", "los", "15", "días", "de", "evolución", ",", "se", "objetivaron", "cambios", "en", "la", "conducción", "sensitiva", "de", "varios", "nervios", ",", "que", "previamente", "no", "habían", "mostrado", "alteraciones", ".", "Éstos", "incluyeron", ",", "reducción", "de", "la", "amplitud", "del", "potencial", "sensitivo", "del", "nervio", "peroneal", "superficial", "izquierdo", ",", "ausencia", "de", "respuestas", "sensitivas", "en", "los", "nervios", "surales", "y", "en", "el", "mediano", "derecho", "al", "estímular", "en", "tercer", "dedo", "y", "disminución", "de", "la", "amplitud", "de", "los", "obtenidos", "desde", "primer", "y", "segundo", "dedos", ".", "Como", "en", "el", "primer", "estudio", ",", "no", "se", "obtuvo", "PM", "del", "CPE", "izquierdo", ".", "La", "amplitud", "de", "los", "PMs", "del", "mediano", "derecho", "estaba", "reducida", ",", "incluyendo", "la", "correspondiente", "a", "la", "estimulación", "en", "la", "palma", ",", "que", "había", "disminuido", "respecto", "a", "la", "del", "estudio", "previo", ".", "En", "el", "EMG", "se", "registró", "actividad", "espontánea", "en", "forma", "de", "fibrilaciones", "y", "ondas", "positivas", ",", "abundantes", "en", "el", "ACP", "derecho", "y", "escasas", "en", "TA", "y", "pedio", "izquierdos", ".", "Como", "en", "el", "estudio", "anterior", ",", "el", "reflejo", "H", "y", "las", "ondas", "F", "de", "cubitales", ",", "tibiales", "posteriores", ",", "mediano", "izquierdo", "y", "CPE", "derecho", "fueron", "normales", "y", "no", "se", "observaron", "bloqueos", "proximales", "de", "la", "conducción", "motora", "en", "el", "mediano", "izquierdo", "y", "en", "ambos", "cubitales", ",", "obteniéndose", "valores", "normales", "hasta", "punto", "de", "Erb", ".", "\n", "Se", "realizó", "una", "biopsia", "del", "nervio", "sural", "izquierdo", ",", "que", "mostró", "degeneración", "axonal", "e", "infiltrado", "inflamatorio", "perivascular", "compatible", "con", "infarto", "por", "vasculitis", ".", "\n", "Se", "instauró", "tratamiento", "con", "60", "mg", "/", "día", "de", "prednisona", ",", "con", "mejoría", "subjetiva", "de", "la", "debilidad", "muscular", "y", "de", "las", "parestesias", "dolorosas", ".", "Posteriormente", "se", "redujo", "gradualmente", "la", "dosis", "de", "prednisona", ".", "A", "los", "9", "meses", ",", "45", "mg", "a", "días", "alternos", ",", "mejoría", "de", "parestesias", "en", "las", "extremidades", "inferiores", "y", "de", "fuerza", "proximal", "en", "la", "extremidad", "superior", "izquierda", ".", "Persistía", "déficit", "sensitivomotor", "en", "la", "mano", "derecha", "y", "paresia", "marcada", "en", "territorio", "del", "CPE", "izquierdo", ".", "Un", "tercer", "estudio", "neurofisiológico", "realizado", "a", "los", "9", "meses", "no", "mostro", "cambios", "significativos", "respecto", "al", "anterior", ",", "excepto", "la", "reaparición", "del", "potencial", "sensitivo", "de", "baja", "amplitud", "en", "el", "nervio", "sural", "derecho", ".", "En", "el", "EMG", "persistía", "moderada", "actividad", "espontánea", "en", "ACP", "derecho", "y", "TA", "izquierdo", ",", "con", "patrones", "de", "máximo", "esfuerzo", "marcadamente", "deficitarios", "y", "PUMs", "con", "signos", "de", "reinervación", "activa", ",", "irregulares", "(", "polifásicos", "y", "politurns", ")", "e", "inestables", ".", "\n", "Remitido", "por", ":", "Rocío", "Milena", "Pabón", "Meneses", "Servicio", "de", "Neurofisiología", "Clínica", "Hospital", "Virgen", "del", "Camino", "Ronda", "Cendea", "de", "Zizur", ",", "58", "-", "2ºC", "31010", "Barañain", ".", "Navarra", "Tfno.+34679802102", "E", "-", "mail", ":", "drarociomilena@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

antioxidants is an other_organic_compound, tumor necrosis factor - alpha is a protein_molecule, IL - beta is a protein_molecule, IL-6 is a protein_molecule, human peripheral blood mononuclear cells is a cell_type

12992_task0

Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_type, protein_molecule

[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.

[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]

[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]

antioxidants is an other_organic_compound, tumor necrosis factor - alpha is a protein_molecule, IL - beta is a protein_molecule, IL-6 is a protein_molecule, human peripheral blood mononuclear cells is a cell_type

12992_task1

Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please typing these entity words according to sentence: antioxidants, tumor necrosis factor - alpha, IL - beta, IL-6, human peripheral blood mononuclear cells Options: other_organic_compound, cell_type, protein_molecule

[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.

[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]

[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]

antioxidants, tumor necrosis factor - alpha, IL - beta, IL-6, human peripheral blood mononuclear cells

12992_task2

Sentence: Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Instructions: please extract entity words from the input sentence

[ "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells.

[ "Some", "antioxidants", "inhibit", ",", "in", "a", "co", "-", "ordinate", "fashion", ",", "the", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", ",", "IL", "-", "beta", ",", "and", "IL-6", "by", "human", "peripheral", "blood", "mononuclear", "cells", "." ]

[ "cell_type", "protein_molecule", "other_name", "protein_family_or_group", "other_organic_compound", "lipid", "cell_component", "RNA_family_or_group", "DNA_domain_or_region", "mono_cell", "DNA_family_or_group", "multi_cell" ]

ADAM 12 is a protein, p85alpha is a protein, phosphatidylinositol 3-kinase is a protein

HPRD50.d11_task0

Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]

Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells

[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]

[ "protein" ]

ADAM 12 is a protein, p85alpha is a protein, phosphatidylinositol 3-kinase is a protein

HPRD50.d11_task1

Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please typing these entity words according to sentence: ADAM 12, p85alpha, phosphatidylinositol 3-kinase Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]

Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells

[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]

[ "protein" ]

ADAM 12, p85alpha, phosphatidylinositol 3-kinase

HPRD50.d11_task2

Sentence: Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "I-protein", "O", "O", "O" ]

Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells

[ "Direct", "interaction", "between", "the", "cytoplasmic", "tail", "of", "ADAM", "12", "and", "the", "Src", "homology", "3", "domain", "of", "p85alpha", "activates", "phosphatidylinositol", "3-kinase", "in", "C2C12", "cells" ]

[ "protein" ]

factor VIIa is a Protein, coagulation factor VII is a Protein, factor VIIa is a Protein, factor X is a Protein, factor IX is a Protein, tissue factor is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, asparagine residues is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, Asparagine residues 145 is a Entity, 322 is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, asparagine residue 322 is a Entity, asparagine residue 145 is a Entity, factor VIIa is a Protein

515_task0

Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)

[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

factor VIIa is a Protein, coagulation factor VII is a Protein, factor VIIa is a Protein, factor X is a Protein, factor IX is a Protein, tissue factor is a Protein, factor VIIa is a Protein, aspartic acid residue is a Entity, asparagine residues is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, factor VIIa is a Protein, Asparagine residues 145 is a Entity, 322 is a Entity, factor VIIa is a Protein, factor VIIa is a Protein, asparagine residue 322 is a Entity, asparagine residue 145 is a Entity, factor VIIa is a Protein

515_task1

Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please typing these entity words according to sentence: factor VIIa, coagulation factor VII, factor VIIa, factor X, factor IX, tissue factor, factor VIIa, aspartic acid residue, asparagine residues, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, Asparagine residues 145, 322, factor VIIa, factor VIIa, asparagine residue 322, asparagine residue 145, factor VIIa Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)

[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

factor VIIa, coagulation factor VII, factor VIIa, factor X, factor IX, tissue factor, factor VIIa, aspartic acid residue, asparagine residues, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, factor VIIa, Asparagine residues 145, 322, factor VIIa, factor VIIa, asparagine residue 322, asparagine residue 145, factor VIIa

515_task2

Sentence: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS) Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Blood coagulation factor VII is a vitamin K dependent glycoprotein which in its activated form, factor VIIa, participates in the coagulation process by activating factor X and/or factor IX in the presence of Ca2+ and tissue factor. Three types of potential posttranslational modifications exist in the human factor VIIa molecule, namely, 10 gamma-carboxylated, N-terminally located glutamic acid residues, 1 beta-hydroxylated aspartic acid residue, and 2 N-glycosylated asparagine residues. In the present study, the amino acid sequence and posttranslational modifications of recombinant factor VIIa as purified from the culture medium of a transfected baby hamster kidney cell line have been compared to human plasma factor VIIa. By use of HPLC, amino acid analysis, peptide mapping, and automated Edman degradations, the protein backbone of recombinant factor VIIa was found to be identical with human factor VIIa. Neither recombinant factor VIIa nor human plasma factor VIIa was found to contain beta-hydroxyaspartic acid. In human plasma factor VIIa, the 10 N-terminally located glutamic acid residues were found to be fully gamma-carboxylated whereas 9 full and 1 partial gamma-carboxylated residues were found in the corresponding positions of the recombinant factor VIIa molecule. Asparagine residues 145 and 322 were found to be fully N-glycosylated in human plasma factor VIIa. In the recombinant factor VIIa, asparagine residue 322 was fully glycosylated whereas asparagine residue 145 was only partially (approximately 66%) glycosylated. Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)

[ "Amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "human", "factor", "VIIa", "from", "plasma", "and", "transfected", "baby", "hamster", "kidney", "cells", ".", "\n", "Blood", "coagulation", "factor", "VII", "is", "a", "vitamin", "K", "dependent", "glycoprotein", "which", "in", "its", "activated", "form", ",", "factor", "VIIa", ",", "participates", "in", "the", "coagulation", "process", "by", "activating", "factor", "X", "and", "/", "or", "factor", "IX", "in", "the", "presence", "of", "Ca2", "+", "and", "tissue", "factor", ".", "Three", "types", "of", "potential", "posttranslational", "modifications", "exist", "in", "the", "human", "factor", "VIIa", "molecule", ",", "namely", ",", "10", "gamma", "-", "carboxylated", ",", "N", "-", "terminally", "located", "glutamic", "acid", "residues", ",", "1", "beta", "-", "hydroxylated", "aspartic", "acid", "residue", ",", "and", "2", "N", "-", "glycosylated", "asparagine", "residues", ".", "In", "the", "present", "study", ",", "the", "amino", "acid", "sequence", "and", "posttranslational", "modifications", "of", "recombinant", "factor", "VIIa", "as", "purified", "from", "the", "culture", "medium", "of", "a", "transfected", "baby", "hamster", "kidney", "cell", "line", "have", "been", "compared", "to", "human", "plasma", "factor", "VIIa", ".", "By", "use", "of", "HPLC", ",", "amino", "acid", "analysis", ",", "peptide", "mapping", ",", "and", "automated", "Edman", "degradations", ",", "the", "protein", "backbone", "of", "recombinant", "factor", "VIIa", "was", "found", "to", "be", "identical", "with", "human", "factor", "VIIa", ".", "Neither", "recombinant", "factor", "VIIa", "nor", "human", "plasma", "factor", "VIIa", "was", "found", "to", "contain", "beta", "-", "hydroxyaspartic", "acid", ".", "In", "human", "plasma", "factor", "VIIa", ",", "the", "10", "N", "-", "terminally", "located", "glutamic", "acid", "residues", "were", "found", "to", "be", "fully", "gamma", "-", "carboxylated", "whereas", "9", "full", "and", "1", "partial", "gamma", "-", "carboxylated", "residues", "were", "found", "in", "the", "corresponding", "positions", "of", "the", "recombinant", "factor", "VIIa", "molecule", ".", "Asparagine", "residues", "145", "and", "322", "were", "found", "to", "be", "fully", "N", "-", "glycosylated", "in", "human", "plasma", "factor", "VIIa", ".", "In", "the", "recombinant", "factor", "VIIa", ",", "asparagine", "residue", "322", "was", "fully", "glycosylated", "whereas", "asparagine", "residue", "145", "was", "only", "partially", "(", "approximately", "66", "%", ")", "glycosylated", ".", "Besides", "minor", "differences", "in", "the", "sialic", "acid", "and", "fucose", "contents", ",", "the", "overall", "carbohydrate", "compositions", "were", "nearly", "identical", "in", "recombinant", "factor", "VIIa", "and", "human", "plasma", "factor", "VIIa.(ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")", "\n" ]

[ "Entity", "Protein" ]

Thorax is an umlsterm, Lymphome is an umlsterm, Lungenerkrankungen is an umlsterm, Pulmonalembolien is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Bronchoskopie is an umlsterm

DerRadiologe.60360457.ger.abstr_task0

Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .

[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]

[ "umlsterm" ]

Thorax is an umlsterm, Lymphome is an umlsterm, Lungenerkrankungen is an umlsterm, Pulmonalembolien is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Bronchoskopie is an umlsterm

DerRadiologe.60360457.ger.abstr_task1

Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please typing these entity words according to sentence: Thorax, Lymphome, Lungenerkrankungen, Pulmonalembolien, Diagnostik, Pathologie, Bronchoskopie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .

[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]

[ "umlsterm" ]

Thorax, Lymphome, Lungenerkrankungen, Pulmonalembolien, Diagnostik, Pathologie, Bronchoskopie

DerRadiologe.60360457.ger.abstr_task2

Sentence: Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Spiral-CT ermoeglicht es , den Thorax innerhalb einer Atemphase kontinuierlich zu erfassen . Im Vergleich zur Standard-CT zeigt die Spiral-CT eine erhoehte Sensitivitaet zum Nachweis intrapulmonaler Rundherde , kleiner mediastinaler und bronchopulmonaler Lymphome , pleuraler Plaques sowie eine verbesserte morphologische Charakterisierung von Laesionen . Neue diagnostische Aufgaben umfassen den Nachweis subtiler diffuser Lungenerkrankungen , den Nachweis von Pulmonalembolien sowie vaskulaerer Malformationen . Fuer die Diagnostik tracheobronchialer Pathologie stellt die Spiral-CT eine ideale Ergaenzung zur Bronchoskopie dar .

[ "Die", "Spiral", "-", "CT", "ermoeglicht", "es", ",", "den", "Thorax", "innerhalb", "einer", "Atemphase", "kontinuierlich", "zu", "erfassen", ".", "Im", "Vergleich", "zur", "Standard", "-", "CT", "zeigt", "die", "Spiral", "-", "CT", "eine", "erhoehte", "Sensitivitaet", "zum", "Nachweis", "intrapulmonaler", "Rundherde", ",", "kleiner", "mediastinaler", "und", "bronchopulmonaler", "Lymphome", ",", "pleuraler", "Plaques", "sowie", "eine", "verbesserte", "morphologische", "Charakterisierung", "von", "Laesionen", ".", "Neue", "diagnostische", "Aufgaben", "umfassen", "den", "Nachweis", "subtiler", "diffuser", "Lungenerkrankungen", ",", "den", "Nachweis", "von", "Pulmonalembolien", "sowie", "vaskulaerer", "Malformationen", ".", "Fuer", "die", "Diagnostik", "tracheobronchialer", "Pathologie", "stellt", "die", "Spiral", "-", "CT", "eine", "ideale", "Ergaenzung", "zur", "Bronchoskopie", "dar", "." ]

[ "umlsterm" ]

in vitro is an umlsterm, Kirschner - Draehte is an umlsterm

DerUnfallchirurg.01030839.ger.abstr_task0

Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .

[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]

[ "umlsterm" ]

in vitro is an umlsterm, Kirschner - Draehte is an umlsterm

DerUnfallchirurg.01030839.ger.abstr_task1

Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please typing these entity words according to sentence: in vitro, Kirschner - Draehte Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .

[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]

[ "umlsterm" ]

in vitro, Kirschner - Draehte

DerUnfallchirurg.01030839.ger.abstr_task2

Sentence: Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit Hilfe eines mechanischen Testverfahrens wurden nach Variation ausgewaehlter Gestaltparameter klinisch eingesetzte Fixateurkonfigurationen in vitro untersucht . Zusaetzlich wurde der Einfluss der passiven Weichteile an humanen Praeparaten ermittelt . Eine Erhoehung der Anzahl der Schanz-Schrauben bzw. der Kirschner-Draehte bewirkte eine vergleichbare Steigerung der Steifigkeit wie eine Erhoehung des Durchmessers der Schrauben bzw. Draehte . Wo klinisch zulaessig , sind daher groessere Durchmesser anstelle einer hoeheren Anzahl der Schrauben bzw. Draehte zu empfehlen .

[ "Mit", "Hilfe", "eines", "mechanischen", "Testverfahrens", "wurden", "nach", "Variation", "ausgewaehlter", "Gestaltparameter", "klinisch", "eingesetzte", "Fixateurkonfigurationen", "in", "vitro", "untersucht", ".", "Zusaetzlich", "wurde", "der", "Einfluss", "der", "passiven", "Weichteile", "an", "humanen", "Praeparaten", "ermittelt", ".", "Eine", "Erhoehung", "der", "Anzahl", "der", "Schanz", "-", "Schrauben", "bzw", ".", "der", "Kirschner", "-", "Draehte", "bewirkte", "eine", "vergleichbare", "Steigerung", "der", "Steifigkeit", "wie", "eine", "Erhoehung", "des", "Durchmessers", "der", "Schrauben", "bzw", ".", "Draehte", ".", "Wo", "klinisch", "zulaessig", ",", "sind", "daher", "groessere", "Durchmesser", "anstelle", "einer", "hoeheren", "Anzahl", "der", "Schrauben", "bzw", ".", "Draehte", "zu", "empfehlen", "." ]

[ "umlsterm" ]

skin cancer is a Outcome_Physical, adults : is a Participant_Age, mailed , tailored intervention is a Intervention_Educational, skin self - examination behaviors is a Outcome_Mental, moderate and high risk for skin cancer is a Participant_Condition, Adults is a Participant_Age, tailored materials , including personalized risk feedback is a Intervention_Educational, general educational materials is a Intervention_Educational, sun protection is a Outcome_Mental, 596 is a Participant_Sample-size, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination is a Outcome_Mental, Tailored communications is a Intervention_Educational, sun - protection behaviors is a Outcome_Mental, increased risk for skin cancer is a Participant_Condition

44540_task0

Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .

[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]

skin cancer is a Outcome_Physical, adults : is a Participant_Age, mailed , tailored intervention is a Intervention_Educational, skin self - examination behaviors is a Outcome_Mental, moderate and high risk for skin cancer is a Participant_Condition, Adults is a Participant_Age, tailored materials , including personalized risk feedback is a Intervention_Educational, general educational materials is a Intervention_Educational, sun protection is a Outcome_Mental, 596 is a Participant_Sample-size, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination is a Outcome_Mental, Tailored communications is a Intervention_Educational, sun - protection behaviors is a Outcome_Mental, increased risk for skin cancer is a Participant_Condition

44540_task1

Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please typing these entity words according to sentence: skin cancer, adults :, mailed , tailored intervention, skin self - examination behaviors, moderate and high risk for skin cancer, Adults, tailored materials , including personalized risk feedback, general educational materials, sun protection, 596, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination, Tailored communications, sun - protection behaviors, increased risk for skin cancer Options: Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .

[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]

skin cancer, adults :, mailed , tailored intervention, skin self - examination behaviors, moderate and high risk for skin cancer, Adults, tailored materials , including personalized risk feedback, general educational materials, sun protection, 596, overall sun - protection habits , the use of hats , the use of sunglasses , and the recency of skin self - examination, Tailored communications, sun - protection behaviors, increased risk for skin cancer

44540_task2

Sentence: A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A randomized trial of tailored skin cancer prevention messages for adults : Project SCAPE . OBJECTIVES We evaluated the impact of a mailed , tailored intervention on skin cancer prevention and skin self-examination behaviors of adults at moderate and high risk for skin cancer . METHODS Adults at moderate and high risk for skin cancer were recruited in primary health care settings in Honolulu , HI , and Long Island , NY . After completing a baseline survey , participants were randomized to 2 groups . The treatment group received tailored materials , including personalized risk feedback , and the control group received general educational materials . Multivariate analyses compared sun protection and skin self-examination between groups , controlling for location , risk level , gender , and age . RESULTS A total of 596 adults completed the trial . The tailored materials had a significant effect on overall sun-protection habits , the use of hats , the use of sunglasses , and the recency of skin self-examination . Some effects were moderated by location and risk level . CONCLUSIONS Tailored communications including personalized risk feedback can improve sun-protection behaviors and skin self-examination among adults at increased risk for skin cancer . These convenient , low-cost interventions can be implemented in a variety of settings and should be tested further to assess their long-term effectiveness .

[ "A", "randomized", "trial", "of", "tailored", "skin", "cancer", "prevention", "messages", "for", "adults", ":", "Project", "SCAPE", ".", "OBJECTIVES", "We", "evaluated", "the", "impact", "of", "a", "mailed", ",", "tailored", "intervention", "on", "skin", "cancer", "prevention", "and", "skin", "self", "-", "examination", "behaviors", "of", "adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", ".", "METHODS", "Adults", "at", "moderate", "and", "high", "risk", "for", "skin", "cancer", "were", "recruited", "in", "primary", "health", "care", "settings", "in", "Honolulu", ",", "HI", ",", "and", "Long", "Island", ",", "NY", ".", "After", "completing", "a", "baseline", "survey", ",", "participants", "were", "randomized", "to", "2", "groups", ".", "The", "treatment", "group", "received", "tailored", "materials", ",", "including", "personalized", "risk", "feedback", ",", "and", "the", "control", "group", "received", "general", "educational", "materials", ".", "Multivariate", "analyses", "compared", "sun", "protection", "and", "skin", "self", "-", "examination", "between", "groups", ",", "controlling", "for", "location", ",", "risk", "level", ",", "gender", ",", "and", "age", ".", "RESULTS", "A", "total", "of", "596", "adults", "completed", "the", "trial", ".", "The", "tailored", "materials", "had", "a", "significant", "effect", "on", "overall", "sun", "-", "protection", "habits", ",", "the", "use", "of", "hats", ",", "the", "use", "of", "sunglasses", ",", "and", "the", "recency", "of", "skin", "self", "-", "examination", ".", "Some", "effects", "were", "moderated", "by", "location", "and", "risk", "level", ".", "CONCLUSIONS", "Tailored", "communications", "including", "personalized", "risk", "feedback", "can", "improve", "sun", "-", "protection", "behaviors", "and", "skin", "self", "-", "examination", "among", "adults", "at", "increased", "risk", "for", "skin", "cancer", ".", "These", "convenient", ",", "low", "-", "cost", "interventions", "can", "be", "implemented", "in", "a", "variety", "of", "settings", "and", "should", "be", "tested", "further", "to", "assess", "their", "long", "-", "term", "effectiveness", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition", "Outcome_Physical", "Participant_Age", "Participant_Sample-size" ]

H-1 histone is a Protein, histones is a Protein, histone H-1 is a Protein, histone is a Protein, histones is a Protein, histone H-3 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, histone is a Protein, histone is a Protein, histone is a Protein

507_task0

Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.

[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]

[ "Protein" ]

H-1 histone is a Protein, histones is a Protein, histone H-1 is a Protein, histone is a Protein, histones is a Protein, histone H-3 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, H-1 is a Protein, histone is a Protein, histone is a Protein, histone is a Protein

507_task1

Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please typing these entity words according to sentence: H-1 histone, histones, histone H-1, histone, histones, histone H-3, H-1, H-1, H-1, H-1, histone, histone, histone Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.

[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]

[ "Protein" ]

H-1 histone, histones, histone H-1, histone, histones, histone H-3, H-1, H-1, H-1, H-1, histone, histone, histone

507_task2

Sentence: Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Displacement and aberrant methylation in vitro of H-1 histone in rat liver nuclei after half-saturation of chromatin with polycations. Radiomethyl incorporation in vitro into Nepsilon-methyllysine of histones from rat liver nuclei incubated in the presence of S-adenosyl[methyl-3H]methionine is stimulated if the polycations polylysines, protamines, or histones are added to the incubation mixture. Maximal stimulation occurs at a cation/nucleotide ratio of 0.5. Past this point stimulation drops, except in the case of very lysine-rich histone H-1, for which the maximal level of incorporation remains constant upon further addition of this histone. Bio-Gel P-10 chromatography, differential precipitation, and gel electrophoresis of radiomethylated histones indicate that although the usual incorporation of radiomethyl into histone H-3 is not affected, active methylation of H-1 occurs in the presence of polycations. Column chromatographic amino acid analysis reveals that the methylation of H-1 will specifically generate Nepsilon-monomethyllysine. Except for this condition, H-1 is never methylated in vivo or in incubated cell nuclei. Because H-1 is the weakest bound histone in chromatin, the above phenomena may be explained by assuming that, within the chromatin, polycations displace the lysine-rich histone towards the nucleosome, which results in its abberant methylation, assuming that the native nucleosome is the seat of the histone lysine methyltransferase.

[ "Displacement", "and", "aberrant", "methylation", "in", "vitro", "of", "H-1", "histone", "in", "rat", "liver", "nuclei", "after", "half", "-", "saturation", "of", "chromatin", "with", "polycations", ".", "\n", "Radiomethyl", "incorporation", "in", "vitro", "into", "Nepsilon", "-", "methyllysine", "of", "histones", "from", "rat", "liver", "nuclei", "incubated", "in", "the", "presence", "of", "S", "-", "adenosyl[methyl-3H]methionine", "is", "stimulated", "if", "the", "polycations", "polylysines", ",", "protamines", ",", "or", "histones", "are", "added", "to", "the", "incubation", "mixture", ".", "Maximal", "stimulation", "occurs", "at", "a", "cation", "/", "nucleotide", "ratio", "of", "0.5", ".", "Past", "this", "point", "stimulation", "drops", ",", "except", "in", "the", "case", "of", "very", "lysine", "-", "rich", "histone", "H-1", ",", "for", "which", "the", "maximal", "level", "of", "incorporation", "remains", "constant", "upon", "further", "addition", "of", "this", "histone", ".", "Bio", "-", "Gel", "P-10", "chromatography", ",", "differential", "precipitation", ",", "and", "gel", "electrophoresis", "of", "radiomethylated", "histones", "indicate", "that", "although", "the", "usual", "incorporation", "of", "radiomethyl", "into", "histone", "H-3", "is", "not", "affected", ",", "active", "methylation", "of", "H-1", "occurs", "in", "the", "presence", "of", "polycations", ".", "Column", "chromatographic", "amino", "acid", "analysis", "reveals", "that", "the", "methylation", "of", "H-1", "will", "specifically", "generate", "Nepsilon", "-", "monomethyllysine", ".", "Except", "for", "this", "condition", ",", "H-1", "is", "never", "methylated", "in", "vivo", "or", "in", "incubated", "cell", "nuclei", ".", "Because", "H-1", "is", "the", "weakest", "bound", "histone", "in", "chromatin", ",", "the", "above", "phenomena", "may", "be", "explained", "by", "assuming", "that", ",", "within", "the", "chromatin", ",", "polycations", "displace", "the", "lysine", "-", "rich", "histone", "towards", "the", "nucleosome", ",", "which", "results", "in", "its", "abberant", "methylation", ",", "assuming", "that", "the", "native", "nucleosome", "is", "the", "seat", "of", "the", "histone", "lysine", "methyltransferase", ".", "\n" ]

[ "Protein" ]

open is an umlsterm, surgery is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, syndrome is an umlsterm, development is an umlsterm, methods is an umlsterm, treatment is an umlsterm, disc prolapses is an umlsterm, procedures is an umlsterm, diagnostic is an umlsterm, therapy is an umlsterm, methods is an umlsterm, fenestration is an umlsterm, chemonucleolysis is an umlsterm, methods is an umlsterm, laser is an umlsterm, procedures is an umlsterm, procedures is an umlsterm, control groups is an umlsterm, therapy is an umlsterm, methods is an umlsterm, retrospective studies is an umlsterm, single is an umlsterm, method is an umlsterm, criteria is an umlsterm, study design is an umlsterm, procedures is an umlsterm, disorders is an umlsterm, criteria is an umlsterm, time is an umlsterm, methods is an umlsterm, procedures is an umlsterm

DerOrthopaede.90280598.eng.abstr_task0

Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .

[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]

[ "umlsterm" ]

open is an umlsterm, surgery is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, syndrome is an umlsterm, development is an umlsterm, methods is an umlsterm, treatment is an umlsterm, disc prolapses is an umlsterm, procedures is an umlsterm, diagnostic is an umlsterm, therapy is an umlsterm, methods is an umlsterm, fenestration is an umlsterm, chemonucleolysis is an umlsterm, methods is an umlsterm, laser is an umlsterm, procedures is an umlsterm, procedures is an umlsterm, control groups is an umlsterm, therapy is an umlsterm, methods is an umlsterm, retrospective studies is an umlsterm, single is an umlsterm, method is an umlsterm, criteria is an umlsterm, study design is an umlsterm, procedures is an umlsterm, disorders is an umlsterm, criteria is an umlsterm, time is an umlsterm, methods is an umlsterm, procedures is an umlsterm

DerOrthopaede.90280598.eng.abstr_task1

Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please typing these entity words according to sentence: open, surgery, complications, open, surgery, syndrome, development, methods, treatment, disc prolapses, procedures, diagnostic, therapy, methods, fenestration, chemonucleolysis, methods, laser, procedures, procedures, control groups, therapy, methods, retrospective studies, single, method, criteria, study design, procedures, disorders, criteria, time, methods, procedures Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .

[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]

[ "umlsterm" ]

open, surgery, complications, open, surgery, syndrome, development, methods, treatment, disc prolapses, procedures, diagnostic, therapy, methods, fenestration, chemonucleolysis, methods, laser, procedures, procedures, control groups, therapy, methods, retrospective studies, single, method, criteria, study design, procedures, disorders, criteria, time, methods, procedures

DerOrthopaede.90280598.eng.abstr_task2

Sentence: The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The discussion on the results of open spinal surgery , in particular , on complications as a result of open surgery , e . g . , the so-called post-discotomy syndrome , has led to the development of less invasive methods , especially for treatment of lumbar disc prolapses . Percutaneous nucleotomy procedures are based on a variety of intradiscal diagnostic and therapy methods , such as discography , retroperitoneal spinal disc fenestration or chemonucleolysis . Since the 1970 s , various methods such as mechanical percutaneous nucleotomy , automated percutaneous nucleotomy , intradiscal laser procedures and , in part , endoscopic intradiscal procedures have been developed and also used clinically . The clinical results vary from 30 % good/very good results to almost 100 % good/very good results , depending on the author and study . It is obvious that not many prospective randomized studies using either conservatively or surgically treated control groups have been conducted . The results of these studies on intradiscal therapy methods are often analyzed more critically and with lower success rates than the partially retrospective studies of a single method , which often have large case numbers , but do not always meet the demanding criteria for scientific study design . To attain good results , percutaneous nucleotomy procedures can only be used to treat select cases of lumbar disc disorders according to strict indication criteria . At the present time it can be concluded that , in comparison to endoscopic und microsurgical methods , percutaneous nucleotomy procedures must be restricted to a small number of cases .

[ "The", "discussion", "on", "the", "results", "of", "open", "spinal", "surgery", ",", "in", "particular", ",", "on", "complications", "as", "a", "result", "of", "open", "surgery", ",", "e", ".", "g", ".", ",", "the", "so", "-", "called", "post", "-", "discotomy", "syndrome", ",", "has", "led", "to", "the", "development", "of", "less", "invasive", "methods", ",", "especially", "for", "treatment", "of", "lumbar", "disc", "prolapses", ".", "Percutaneous", "nucleotomy", "procedures", "are", "based", "on", "a", "variety", "of", "intradiscal", "diagnostic", "and", "therapy", "methods", ",", "such", "as", "discography", ",", "retroperitoneal", "spinal", "disc", "fenestration", "or", "chemonucleolysis", ".", "Since", "the", "1970", "s", ",", "various", "methods", "such", "as", "mechanical", "percutaneous", "nucleotomy", ",", "automated", "percutaneous", "nucleotomy", ",", "intradiscal", "laser", "procedures", "and", ",", "in", "part", ",", "endoscopic", "intradiscal", "procedures", "have", "been", "developed", "and", "also", "used", "clinically", ".", "The", "clinical", "results", "vary", "from", "30", "%", "good", "/", "very", "good", "results", "to", "almost", "100", "%", "good", "/", "very", "good", "results", ",", "depending", "on", "the", "author", "and", "study", ".", "It", "is", "obvious", "that", "not", "many", "prospective", "randomized", "studies", "using", "either", "conservatively", "or", "surgically", "treated", "control", "groups", "have", "been", "conducted", ".", "The", "results", "of", "these", "studies", "on", "intradiscal", "therapy", "methods", "are", "often", "analyzed", "more", "critically", "and", "with", "lower", "success", "rates", "than", "the", "partially", "retrospective", "studies", "of", "a", "single", "method", ",", "which", "often", "have", "large", "case", "numbers", ",", "but", "do", "not", "always", "meet", "the", "demanding", "criteria", "for", "scientific", "study", "design", ".", "To", "attain", "good", "results", ",", "percutaneous", "nucleotomy", "procedures", "can", "only", "be", "used", "to", "treat", "select", "cases", "of", "lumbar", "disc", "disorders", "according", "to", "strict", "indication", "criteria", ".", "At", "the", "present", "time", "it", "can", "be", "concluded", "that", ",", "in", "comparison", "to", "endoscopic", "und", "microsurgical", "methods", ",", "percutaneous", "nucleotomy", "procedures", "must", "be", "restricted", "to", "a", "small", "number", "of", "cases", "." ]

[ "umlsterm" ]

beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA

416_task0

Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).

[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]

[ "Gene/protein/RNA" ]

beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA

416_task1

Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please typing these entity words according to sentence: beta - catenin, E - cadherin, alpha - catenin Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).

[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]

[ "Gene/protein/RNA" ]

beta - catenin, E - cadherin, alpha - catenin

416_task2

Sentence: In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In cancerous tissues, the frequency of reduced expression of beta-catenin (28 of 86, 33%) was similar to that of E-cadherin (19 of 86, 22%), but less than that of alpha-catenin (47 of 86, 55%).

[ "In", "cancerous", "tissues", ",", "the", "frequency", "of", "reduced", "expression", "of", "beta", "-", "catenin", "(", "28", "of", "86", ",", "33", "%", ")", "was", "similar", "to", "that", "of", "E", "-", "cadherin", "(", "19", "of", "86", ",", "22", "%", ")", ",", "but", "less", "than", "that", "of", "alpha", "-", "catenin", "(", "47", "of", "86", ",", "55", "%", ")", "." ]

[ "Gene/protein/RNA" ]

Erythroid gene expression is an other_name, erythropoietin is a protein_molecule, haemin is an other_organic_compound, delta - aminolaevulinic acid is an other_organic_compound, UT-7 cells is a cell_line

42970_task0

Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_line, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]

Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.

[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]

[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]

Erythroid gene expression is an other_name, erythropoietin is a protein_molecule, haemin is an other_organic_compound, delta - aminolaevulinic acid is an other_organic_compound, UT-7 cells is a cell_line

42970_task1

Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please typing these entity words according to sentence: Erythroid gene expression, erythropoietin, haemin, delta - aminolaevulinic acid, UT-7 cells Options: other_organic_compound, cell_line, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]

Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.

[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]

[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]

Erythroid gene expression, erythropoietin, haemin, delta - aminolaevulinic acid, UT-7 cells

42970_task2

Sentence: Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-protein_molecule", "O", "B-other_organic_compound", "O", "B-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "I-other_organic_compound", "O", "B-cell_line", "I-cell_line", "O" ]

Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells.

[ "Erythroid", "gene", "expression", "is", "differentially", "regulated", "by", "erythropoietin", ",", "haemin", "and", "delta", "-", "aminolaevulinic", "acid", "in", "UT-7", "cells", "." ]

[ "protein_N/A", "protein_molecule", "(AND other_name other_name)", "other_name", "other_organic_compound", "cell_line", "(AND protein_molecule protein_molecule)", "", "protein_family_or_group" ]

training is an umlsterm, patients is an umlsterm, stages is an umlsterm, disease is an umlsterm, patient is an umlsterm, diagnosis is an umlsterm, mobilization is an umlsterm, depressive symptoms is an umlsterm

ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task0

Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .

[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]

[ "umlsterm" ]

training is an umlsterm, patients is an umlsterm, stages is an umlsterm, disease is an umlsterm, patient is an umlsterm, diagnosis is an umlsterm, mobilization is an umlsterm, depressive symptoms is an umlsterm

ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task1

Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please typing these entity words according to sentence: training, patients, stages, disease, patient, diagnosis, mobilization, depressive symptoms Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .

[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]

[ "umlsterm" ]

training, patients, stages, disease, patient, diagnosis, mobilization, depressive symptoms

ZfuerGerontologie+Geriatrie.80310112.eng.abstr_task2

Sentence: At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

At the Psychiatric Department , Ludwig-Maximilians-Universitaet , Munich , a behavioral competency training ( Verhaltenstherapeutisches Kompetenztraining ) VKT is offered to patients with early stages of Alzheimer's disease ( AD ) . The primary objects of VKT are , ( a ) patient support in coping with the diagnosis of AD , ( b ) mobilization of the present personal activity ressources , and ( c ) minimization of depressive symptoms .

[ "At", "the", "Psychiatric", "Department", ",", "Ludwig", "-", "Maximilians", "-", "Universitaet", ",", "Munich", ",", "a", "behavioral", "competency", "training", "(", "Verhaltenstherapeutisches", "Kompetenztraining", ")", "VKT", "is", "offered", "to", "patients", "with", "early", "stages", "of", "Alzheimer", "'s", "disease", "(", "AD", ")", ".", "The", "primary", "objects", "of", "VKT", "are", ",", "(", "a", ")", "patient", "support", "in", "coping", "with", "the", "diagnosis", "of", "AD", ",", "(", "b", ")", "mobilization", "of", "the", "present", "personal", "activity", "ressources", ",", "and", "(", "c", ")", "minimization", "of", "depressive", "symptoms", "." ]

[ "umlsterm" ]

Periduralanalgesie is an umlsterm, Komplikationen is an umlsterm, erwachsenen is an umlsterm, Patienten is an umlsterm, Verwendung is an umlsterm, Kombinationsloesung is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Trauma is an umlsterm, Darmfunktion is an umlsterm, Nausea is an umlsterm, Juckreiz is an umlsterm, Patienten is an umlsterm, Muskelschwaeche is an umlsterm, Beine is an umlsterm, Komplikationen is an umlsterm, Patient is an umlsterm, Hypoxie is an umlsterm, Boden is an umlsterm, Minderperfusion is an umlsterm, Patienten is an umlsterm, Haematome is an umlsterm, Abszesse is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Komplikationen is an umlsterm, Auge is an umlsterm

DerUrologeA.00390041.ger.abstr_task0

Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .

[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]

[ "umlsterm" ]

Periduralanalgesie is an umlsterm, Komplikationen is an umlsterm, erwachsenen is an umlsterm, Patienten is an umlsterm, Verwendung is an umlsterm, Kombinationsloesung is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Trauma is an umlsterm, Darmfunktion is an umlsterm, Nausea is an umlsterm, Juckreiz is an umlsterm, Patienten is an umlsterm, Muskelschwaeche is an umlsterm, Beine is an umlsterm, Komplikationen is an umlsterm, Patient is an umlsterm, Hypoxie is an umlsterm, Boden is an umlsterm, Minderperfusion is an umlsterm, Patienten is an umlsterm, Haematome is an umlsterm, Abszesse is an umlsterm, Analgesie is an umlsterm, Patientenzufriedenheit is an umlsterm, Komplikationen is an umlsterm, Auge is an umlsterm

DerUrologeA.00390041.ger.abstr_task1

Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please typing these entity words according to sentence: Periduralanalgesie, Komplikationen, erwachsenen, Patienten, Verwendung, Kombinationsloesung, Analgesie, Patientenzufriedenheit, Trauma, Darmfunktion, Nausea, Juckreiz, Patienten, Muskelschwaeche, Beine, Komplikationen, Patient, Hypoxie, Boden, Minderperfusion, Patienten, Haematome, Abszesse, Analgesie, Patientenzufriedenheit, Komplikationen, Auge Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .

[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]

[ "umlsterm" ]

Periduralanalgesie, Komplikationen, erwachsenen, Patienten, Verwendung, Kombinationsloesung, Analgesie, Patientenzufriedenheit, Trauma, Darmfunktion, Nausea, Juckreiz, Patienten, Muskelschwaeche, Beine, Komplikationen, Patient, Hypoxie, Boden, Minderperfusion, Patienten, Haematome, Abszesse, Analgesie, Patientenzufriedenheit, Komplikationen, Auge

DerUrologeA.00390041.ger.abstr_task2

Sentence: Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Waehrend die guenstigen Effekte der kontinuierlichen Periduralanalgesie ( PDA ) hinlaenglich bekannt sind , stellt sich die Frage , bei welchen operativen Eingriffen die Indikation zu diesem Verfahren zu stellen ist und mit welchen Nebenwirkungen und Komplikationen zu rechnen ist . Hierfuer untersuchten wir die Unterschiede der PDA in Wirkung und Nebenwirkungen prospektiv an 172 erwachsenen Patienten in Abhaengigkeit vom durchgefuehrten operativen Eingriff . Verwendung fand eine Kombinationsloesung , welche fuer die Dauer von 5-7 Tagen kontinuierlich appliziert wurde . Keine Unterschiede fanden sich in bezug auf die ausgezeichnete Analgesie und Patientenzufriedenheit . Die Mobilisation war je nach vorangegangenem Eingriff erwartungsgemaess unterschiedlich , auch nach maximalem operativen Trauma jedoch beeindruckend problemlos . Ein verzoegertes Einsetzen einer geregelten Darmfunktion nach transperitonealem Eingriff und z . T. auch nach Lumbotomie gegenueber extraperitonealem Unterbaucheingriff ist eingriffsbedingt und z . T. dosisabhaengig . Nebenwirkungen wie Sedierung , Nausea und Juckreiz waren geringgradig sehr haeufig zu finden , eine strenge Dosiskorrelation war jedoch nicht zu erkennen . Z. T. duerften die Nebenwirkungen eingriffsbedingt sein . Bis zu 11 % der Patienten berichteten anfaenglich ueber eine leichte Muskelschwaeche der Beine . Komplikationen : 1 Patient verstarb nach initial unbemerkter intraduraler Katheterlage durch eine cerebrale Hypoxie auf dem Boden einer vorbestehenden gravierenden cerebralen Minderperfusion . Abbruch der PDA bei 4 Patienten wegen falscher Katheterlage . Haematome Abszesse oder bleibende neurologische Schaeden , wurden nicht beobachtet . Die PDA ist in bezug auf Analgesie , Mobilisation und Patientenzufriedenheit ein bewaehrtes Verfahren , sofern die moeglichen Nebenwirkungen und Komplikationen sorgfaeltig im Auge behalten werden . Das Verfahren kann fuer grosse Lumbotomien und ausgedehnte transabdominelle Eingriffe empfohlen werden , nicht jedoch fuer extraperitoneale Unterbaucheingriffe , wie die radikale Prostatektomie .

[ "Waehrend", "die", "guenstigen", "Effekte", "der", "kontinuierlichen", "Periduralanalgesie", "(", "PDA", ")", "hinlaenglich", "bekannt", "sind", ",", "stellt", "sich", "die", "Frage", ",", "bei", "welchen", "operativen", "Eingriffen", "die", "Indikation", "zu", "diesem", "Verfahren", "zu", "stellen", "ist", "und", "mit", "welchen", "Nebenwirkungen", "und", "Komplikationen", "zu", "rechnen", "ist", ".", "Hierfuer", "untersuchten", "wir", "die", "Unterschiede", "der", "PDA", "in", "Wirkung", "und", "Nebenwirkungen", "prospektiv", "an", "172", "erwachsenen", "Patienten", "in", "Abhaengigkeit", "vom", "durchgefuehrten", "operativen", "Eingriff", ".", "Verwendung", "fand", "eine", "Kombinationsloesung", ",", "welche", "fuer", "die", "Dauer", "von", "5", "-", "7", "Tagen", "kontinuierlich", "appliziert", "wurde", ".", "Keine", "Unterschiede", "fanden", "sich", "in", "bezug", "auf", "die", "ausgezeichnete", "Analgesie", "und", "Patientenzufriedenheit", ".", "Die", "Mobilisation", "war", "je", "nach", "vorangegangenem", "Eingriff", "erwartungsgemaess", "unterschiedlich", ",", "auch", "nach", "maximalem", "operativen", "Trauma", "jedoch", "beeindruckend", "problemlos", ".", "Ein", "verzoegertes", "Einsetzen", "einer", "geregelten", "Darmfunktion", "nach", "transperitonealem", "Eingriff", "und", "z", ".", "T.", "auch", "nach", "Lumbotomie", "gegenueber", "extraperitonealem", "Unterbaucheingriff", "ist", "eingriffsbedingt", "und", "z", ".", "T.", "dosisabhaengig", ".", "Nebenwirkungen", "wie", "Sedierung", ",", "Nausea", "und", "Juckreiz", "waren", "geringgradig", "sehr", "haeufig", "zu", "finden", ",", "eine", "strenge", "Dosiskorrelation", "war", "jedoch", "nicht", "zu", "erkennen", ".", "Z.", "T.", "duerften", "die", "Nebenwirkungen", "eingriffsbedingt", "sein", ".", "Bis", "zu", "11", "%", "der", "Patienten", "berichteten", "anfaenglich", "ueber", "eine", "leichte", "Muskelschwaeche", "der", "Beine", ".", "Komplikationen", ":", "1", "Patient", "verstarb", "nach", "initial", "unbemerkter", "intraduraler", "Katheterlage", "durch", "eine", "cerebrale", "Hypoxie", "auf", "dem", "Boden", "einer", "vorbestehenden", "gravierenden", "cerebralen", "Minderperfusion", ".", "Abbruch", "der", "PDA", "bei", "4", "Patienten", "wegen", "falscher", "Katheterlage", ".", "Haematome", "Abszesse", "oder", "bleibende", "neurologische", "Schaeden", ",", "wurden", "nicht", "beobachtet", ".", "Die", "PDA", "ist", "in", "bezug", "auf", "Analgesie", ",", "Mobilisation", "und", "Patientenzufriedenheit", "ein", "bewaehrtes", "Verfahren", ",", "sofern", "die", "moeglichen", "Nebenwirkungen", "und", "Komplikationen", "sorgfaeltig", "im", "Auge", "behalten", "werden", ".", "Das", "Verfahren", "kann", "fuer", "grosse", "Lumbotomien", "und", "ausgedehnte", "transabdominelle", "Eingriffe", "empfohlen", "werden", ",", "nicht", "jedoch", "fuer", "extraperitoneale", "Unterbaucheingriffe", ",", "wie", "die", "radikale", "Prostatektomie", "." ]

[ "umlsterm" ]

disease is an umlsterm, erythema is an umlsterm, oedema is an umlsterm, face is an umlsterm, literature is an umlsterm, lymphoedema is an umlsterm, oedema is an umlsterm, acne is an umlsterm, rosacea is an umlsterm, laboratory is an umlsterm, findings is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm

DerHautarzt.50460796.eng.abstr_task0

Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .

[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]

[ "umlsterm" ]

disease is an umlsterm, erythema is an umlsterm, oedema is an umlsterm, face is an umlsterm, literature is an umlsterm, lymphoedema is an umlsterm, oedema is an umlsterm, acne is an umlsterm, rosacea is an umlsterm, laboratory is an umlsterm, findings is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm

DerHautarzt.50460796.eng.abstr_task1

Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please typing these entity words according to sentence: disease, erythema, oedema, face, literature, lymphoedema, oedema, acne, rosacea, laboratory, findings, therapeutic, measures Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .

[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]

[ "umlsterm" ]

disease, erythema, oedema, face, literature, lymphoedema, oedema, acne, rosacea, laboratory, findings, therapeutic, measures

DerHautarzt.50460796.eng.abstr_task2

Sentence: Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Morbihan's disease was first reported as a distinct entity in 1957 by Degos , describing a chronic persistent erythema and oedema of the upper half of the face . Such conditions have been noted in the literature designated as chronic lymphoedema or solid persistent facial oedema in acne or rosacea . The characteristic features are a chronic course , a typical clinical picture , lack of specific laboratory and histological findings and refractoriness to therapeutic measures .

[ "Morbihan", "'s", "disease", "was", "first", "reported", "as", "a", "distinct", "entity", "in", "1957", "by", "Degos", ",", "describing", "a", "chronic", "persistent", "erythema", "and", "oedema", "of", "the", "upper", "half", "of", "the", "face", ".", "Such", "conditions", "have", "been", "noted", "in", "the", "literature", "designated", "as", "chronic", "lymphoedema", "or", "solid", "persistent", "facial", "oedema", "in", "acne", "or", "rosacea", ".", "The", "characteristic", "features", "are", "a", "chronic", "course", ",", "a", "typical", "clinical", "picture", ",", "lack", "of", "specific", "laboratory", "and", "histological", "findings", "and", "refractoriness", "to", "therapeutic", "measures", "." ]

[ "umlsterm" ]

nitric oxide is an umlsterm, vasodilatation is an umlsterm, relaxation is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, platelet aggregation is an umlsterm, Animal experiments is an umlsterm, production is an umlsterm, pregnancy is an umlsterm, vascular resistance is an umlsterm, glomerular filtration rate is an umlsterm, Inhibition is an umlsterm, preeclampsia - like is an umlsterm, syndrome is an umlsterm, animal is an umlsterm, in vitro is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, deficiency is an umlsterm, vasoconstriction is an umlsterm, preeclampsia is an umlsterm, half - life is an umlsterm, time is an umlsterm, drugs is an umlsterm, glycerol is an umlsterm, nitroglycerine is an umlsterm, isosorbide dinitrate is an umlsterm, ISDN is an umlsterm, isosorbide mononitrate is an umlsterm, use is an umlsterm, donors is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, knowledge is an umlsterm, pregnancy is an umlsterm, minor is an umlsterm, blood pressure is an umlsterm, perfusion is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, prophylaxis is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, women is an umlsterm, risk is an umlsterm, development is an umlsterm, disease is an umlsterm, sample size is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, literature is an umlsterm, use is an umlsterm, donors is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, clinical trials is an umlsterm

DerGynaekologe.90320768.eng.abstr_task0

Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .

[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]

[ "umlsterm" ]

nitric oxide is an umlsterm, vasodilatation is an umlsterm, relaxation is an umlsterm, smooth muscle is an umlsterm, cells is an umlsterm, platelet aggregation is an umlsterm, Animal experiments is an umlsterm, production is an umlsterm, pregnancy is an umlsterm, vascular resistance is an umlsterm, glomerular filtration rate is an umlsterm, Inhibition is an umlsterm, preeclampsia - like is an umlsterm, syndrome is an umlsterm, animal is an umlsterm, in vitro is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, deficiency is an umlsterm, vasoconstriction is an umlsterm, preeclampsia is an umlsterm, half - life is an umlsterm, time is an umlsterm, drugs is an umlsterm, glycerol is an umlsterm, nitroglycerine is an umlsterm, isosorbide dinitrate is an umlsterm, ISDN is an umlsterm, isosorbide mononitrate is an umlsterm, use is an umlsterm, donors is an umlsterm, human is an umlsterm, pregnancy is an umlsterm, knowledge is an umlsterm, pregnancy is an umlsterm, minor is an umlsterm, blood pressure is an umlsterm, perfusion is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, prophylaxis is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, women is an umlsterm, risk is an umlsterm, development is an umlsterm, disease is an umlsterm, sample size is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, donors is an umlsterm, literature is an umlsterm, use is an umlsterm, donors is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, preeclampsia is an umlsterm, clinical trials is an umlsterm

DerGynaekologe.90320768.eng.abstr_task1

Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please typing these entity words according to sentence: nitric oxide, vasodilatation, relaxation, smooth muscle, cells, platelet aggregation, Animal experiments, production, pregnancy, vascular resistance, glomerular filtration rate, Inhibition, preeclampsia - like, syndrome, animal, in vitro, human, pregnancy, deficiency, vasoconstriction, preeclampsia, half - life, time, drugs, glycerol, nitroglycerine, isosorbide dinitrate, ISDN, isosorbide mononitrate, use, donors, human, pregnancy, knowledge, pregnancy, minor, blood pressure, perfusion, patients, preeclampsia, prophylaxis, preeclampsia, donors, women, risk, development, disease, sample size, therapy, preeclampsia, donors, literature, use, donors, prophylaxis, therapy, preeclampsia, clinical trials Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .

[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]

[ "umlsterm" ]

nitric oxide, vasodilatation, relaxation, smooth muscle, cells, platelet aggregation, Animal experiments, production, pregnancy, vascular resistance, glomerular filtration rate, Inhibition, preeclampsia - like, syndrome, animal, in vitro, human, pregnancy, deficiency, vasoconstriction, preeclampsia, half - life, time, drugs, glycerol, nitroglycerine, isosorbide dinitrate, ISDN, isosorbide mononitrate, use, donors, human, pregnancy, knowledge, pregnancy, minor, blood pressure, perfusion, patients, preeclampsia, prophylaxis, preeclampsia, donors, women, risk, development, disease, sample size, therapy, preeclampsia, donors, literature, use, donors, prophylaxis, therapy, preeclampsia, clinical trials

DerGynaekologe.90320768.eng.abstr_task2

Sentence: Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Endothelially derived nitric oxide ( NO ) regulates vasodilatation via relaxation of the smooth muscle cells and inhibits platelet aggregation in addition to a number of other biological processes . Animal experiments have provided evidence for increased NO production in the normal pregnancy . This contributes to the decrease in peripheral vascular resistance and to the increased glomerular filtration rate . Inhibition of NO synthesis is associated with a preeclampsia-like syndrome in various animal species . In vivo and in vitro data in the human pregnancy have indicated that NO deficiency contributes to the vasoconstriction seen in preeclampsia . However , due to the short half-life time of NO , pharmacological application is only possible by NO-donating drugs such as glycerol trinitrate ( GTN , " nitroglycerine " ) , isosorbide dinitrate ( ISDN ) , isosorbide mononitrate ( ISMN ) or S-nitrosoglutathion ( GSNO ) . There is limited experience with the use of NO donors in human pregnancy ; yet no teratogenic or embryotoxic effects are reported . According to current knowledge , transdermal application of GTN in pregnancy is safe with only minor effects on maternal blood pressure and without compromising the uteroplacental perfusion in patients with preeclampsia . Up to now only one prospective randomized trial has been conducted on the prophylaxis of preeclampsia by NO donors in women at high risk for development of the disease . However , the sample size of this study was too small to allow final conclusions . There are no randomized trials on the therapy of preeclampsia by NO donors reported in the literature . Therefore , it is that the use of NO donors be evaluated in the prophylaxis and therapy of preeclampsia only recommended in the context of clinical trials .

[ "Endothelially", "derived", "nitric", "oxide", "(", "NO", ")", "regulates", "vasodilatation", "via", "relaxation", "of", "the", "smooth", "muscle", "cells", "and", "inhibits", "platelet", "aggregation", "in", "addition", "to", "a", "number", "of", "other", "biological", "processes", ".", "Animal", "experiments", "have", "provided", "evidence", "for", "increased", "NO", "production", "in", "the", "normal", "pregnancy", ".", "This", "contributes", "to", "the", "decrease", "in", "peripheral", "vascular", "resistance", "and", "to", "the", "increased", "glomerular", "filtration", "rate", ".", "Inhibition", "of", "NO", "synthesis", "is", "associated", "with", "a", "preeclampsia", "-", "like", "syndrome", "in", "various", "animal", "species", ".", "In", "vivo", "and", "in", "vitro", "data", "in", "the", "human", "pregnancy", "have", "indicated", "that", "NO", "deficiency", "contributes", "to", "the", "vasoconstriction", "seen", "in", "preeclampsia", ".", "However", ",", "due", "to", "the", "short", "half", "-", "life", "time", "of", "NO", ",", "pharmacological", "application", "is", "only", "possible", "by", "NO", "-", "donating", "drugs", "such", "as", "glycerol", "trinitrate", "(", "GTN", ",", "\"", "nitroglycerine", "\"", ")", ",", "isosorbide", "dinitrate", "(", "ISDN", ")", ",", "isosorbide", "mononitrate", "(", "ISMN", ")", "or", "S", "-", "nitrosoglutathion", "(", "GSNO", ")", ".", "There", "is", "limited", "experience", "with", "the", "use", "of", "NO", "donors", "in", "human", "pregnancy", ";", "yet", "no", "teratogenic", "or", "embryotoxic", "effects", "are", "reported", ".", "According", "to", "current", "knowledge", ",", "transdermal", "application", "of", "GTN", "in", "pregnancy", "is", "safe", "with", "only", "minor", "effects", "on", "maternal", "blood", "pressure", "and", "without", "compromising", "the", "uteroplacental", "perfusion", "in", "patients", "with", "preeclampsia", ".", "Up", "to", "now", "only", "one", "prospective", "randomized", "trial", "has", "been", "conducted", "on", "the", "prophylaxis", "of", "preeclampsia", "by", "NO", "donors", "in", "women", "at", "high", "risk", "for", "development", "of", "the", "disease", ".", "However", ",", "the", "sample", "size", "of", "this", "study", "was", "too", "small", "to", "allow", "final", "conclusions", ".", "There", "are", "no", "randomized", "trials", "on", "the", "therapy", "of", "preeclampsia", "by", "NO", "donors", "reported", "in", "the", "literature", ".", "Therefore", ",", "it", "is", "that", "the", "use", "of", "NO", "donors", "be", "evaluated", "in", "the", "prophylaxis", "and", "therapy", "of", "preeclampsia", "only", "recommended", "in", "the", "context", "of", "clinical", "trials", "." ]

[ "umlsterm" ]

glucagon receptor is a GENE-Y, G protein - coupled receptors is a GENE-N, glucagon is a GENE-Y, GIP is a GENE-Y, GLP-1 is a GENE-Y, GLP-2 receptors is a GENE-Y

12529935_task0

Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.

[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

glucagon receptor is a GENE-Y, G protein - coupled receptors is a GENE-N, glucagon is a GENE-Y, GIP is a GENE-Y, GLP-1 is a GENE-Y, GLP-2 receptors is a GENE-Y

12529935_task1

Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please typing these entity words according to sentence: glucagon receptor, G protein - coupled receptors, glucagon, GIP, GLP-1, GLP-2 receptors Options: GENE-Y, GENE-N

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.

[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

glucagon receptor, G protein - coupled receptors, glucagon, GIP, GLP-1, GLP-2 receptors

12529935_task2

Sentence: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.

[ "Structure", "-", "function", "of", "the", "glucagon", "receptor", "family", "of", "G", "protein", "-", "coupled", "receptors", ":", "the", "glucagon", ",", "GIP", ",", "GLP-1", ",", "and", "GLP-2", "receptors", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

protease is a protein, ammonium is a compound, sulfate is a compound

DS.d4_task0

Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.

[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]

[ "protein", "compound" ]

protease is a protein, ammonium is a compound, sulfate is a compound

DS.d4_task1

Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please typing these entity words according to sentence: protease, ammonium, sulfate Options: compound, protein

[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.

[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]

[ "protein", "compound" ]

protease, ammonium, sulfate

DS.d4_task2

Sentence: The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%. Instructions: please extract entity words from the input sentence

[ "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The protease was purified to homogeneity using ammonium sulfate precipitation, and ion exchange chromatography with a fold purification of 1.8 and a recovery of 49%.

[ "The", "protease", "was", "purified", "to", "homogeneity", "using", "ammonium", "sulfate", "precipitation", ",", "and", "ion", "exchange", "chromatography", "with", "a", "fold", "purification", "of", "1.8", "and", "a", "recovery", "of", "49", "%", "." ]

[ "protein", "compound" ]

Kombinationstherapie is an umlsterm, rheumatoiden Arthritis is an umlsterm, Boden is an umlsterm

ZfuerRheumatologie.80570025.ger.abstr_task0

Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...

[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]

[ "umlsterm" ]

Kombinationstherapie is an umlsterm, rheumatoiden Arthritis is an umlsterm, Boden is an umlsterm

ZfuerRheumatologie.80570025.ger.abstr_task1

Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please typing these entity words according to sentence: Kombinationstherapie, rheumatoiden Arthritis, Boden Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...

[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]

[ "umlsterm" ]

Kombinationstherapie, rheumatoiden Arthritis, Boden

ZfuerRheumatologie.80570025.ger.abstr_task2

Sentence: Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ... Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Kombinationstherapie der rheumatoiden Arthritis will eine bessere Krankheitskontrolle erzielen als die konventionelle Monotherapie . Auf dem Boden vieler klinischer Studien , die mehr oder weniger positive Ergebnisse erbrachten , sind verschiedene Kombinationen untersucht worden : ...

[ "Die", "Kombinationstherapie", "der", "rheumatoiden", "Arthritis", "will", "eine", "bessere", "Krankheitskontrolle", "erzielen", "als", "die", "konventionelle", "Monotherapie", ".", "Auf", "dem", "Boden", "vieler", "klinischer", "Studien", ",", "die", "mehr", "oder", "weniger", "positive", "Ergebnisse", "erbrachten", ",", "sind", "verschiedene", "Kombinationen", "untersucht", "worden", ":", "..." ]

[ "umlsterm" ]

translocons is a Cellular_component, endoplasmic reticulum is a Cellular_component, inner membrane is a Cellular_component, aqueous pore is a Cellular_component, membrane is a Cellular_component, membrane is a Cellular_component, translocation pore is a Cellular_component, cytosolic is a Organism_substance, membrane is a Cellular_component, translocation pore is a Cellular_component, translocon is a Cellular_component, translocon is a Cellular_component, membrane is a Cellular_component, translocon is a Cellular_component

PMID-11716301_task0

Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.

[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]

[ "Cellular_component", "Organism_substance" ]

translocons is a Cellular_component, endoplasmic reticulum is a Cellular_component, inner membrane is a Cellular_component, aqueous pore is a Cellular_component, membrane is a Cellular_component, membrane is a Cellular_component, translocation pore is a Cellular_component, cytosolic is a Organism_substance, membrane is a Cellular_component, translocation pore is a Cellular_component, translocon is a Cellular_component, translocon is a Cellular_component, membrane is a Cellular_component, translocon is a Cellular_component

PMID-11716301_task1

Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please typing these entity words according to sentence: translocons, endoplasmic reticulum, inner membrane, aqueous pore, membrane, membrane, translocation pore, cytosolic, membrane, translocation pore, translocon, translocon, membrane, translocon Options: Cellular_component, Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.

[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]

[ "Cellular_component", "Organism_substance" ]

translocons, endoplasmic reticulum, inner membrane, aqueous pore, membrane, membrane, translocation pore, cytosolic, membrane, translocation pore, translocon, translocon, membrane, translocon

PMID-11716301_task2

Sentence: Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Assembly strategies and GTPase regulation of the eukaryotic and Escherichia coil translocons. The translocation of most proteins across the endoplasmic reticulum or bacterial inner membrane occurs through an aqueous pore that spans the membrane. Substrates that are translocated co-translationally across the membrane are directed to the translocation pore via an interaction between the cytosolic signal recognition particle and its membrane-bound receptor. Together the translocation pore and the receptor are referred to as a translocon. By studying the biogenesis of the translocon a number of alternate targeting and membrane-integration pathways have been discovered that operate independently of the signal recognition particle (SRP) pathway. The novel assembly strategies of the translocon and the ways in which these components interact to ensure the fidelity and unidirectionality of the targeting and translocation process are reviewed here.

[ "Assembly", "strategies", "and", "GTPase", "regulation", "of", "the", "eukaryotic", "and", "Escherichia", "coil", "translocons", ".", "\n", "The", "translocation", "of", "most", "proteins", "across", "the", "endoplasmic", "reticulum", "or", "bacterial", "inner", "membrane", "occurs", "through", "an", "aqueous", "pore", "that", "spans", "the", "membrane", ".", "Substrates", "that", "are", "translocated", "co", "-", "translationally", "across", "the", "membrane", "are", "directed", "to", "the", "translocation", "pore", "via", "an", "interaction", "between", "the", "cytosolic", "signal", "recognition", "particle", "and", "its", "membrane", "-", "bound", "receptor", ".", "Together", "the", "translocation", "pore", "and", "the", "receptor", "are", "referred", "to", "as", "a", "translocon", ".", "By", "studying", "the", "biogenesis", "of", "the", "translocon", "a", "number", "of", "alternate", "targeting", "and", "membrane", "-", "integration", "pathways", "have", "been", "discovered", "that", "operate", "independently", "of", "the", "signal", "recognition", "particle", "(", "SRP", ")", "pathway", ".", "The", "novel", "assembly", "strategies", "of", "the", "translocon", "and", "the", "ways", "in", "which", "these", "components", "interact", "to", "ensure", "the", "fidelity", "and", "unidirectionality", "of", "the", "targeting", "and", "translocation", "process", "are", "reviewed", "here", ".", "\n" ]

[ "Cellular_component", "Organism_substance" ]

Lc753 - 893 is a protein-region, II - III loop is a protein-region, domains II - III is a protein-domain, CaV1.2 α1 is a protein, GST - C2A wt is an experimental-construct, GST - C2A * mutant is an experimental-construct, Biacore AB is a brand, glutathione - S - transferase is a protein-family, GST is an experiment-tag, GST - agarose beads is a reagent

1.0alpha7.train.1355_task0

Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, brand, experimental-construct, protein-domain, experiment-tag, reagent, protein, protein-region

[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]

The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.

[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]

[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]

Lc753 - 893 is a protein-region, II - III loop is a protein-region, domains II - III is a protein-domain, CaV1.2 α1 is a protein, GST - C2A wt is an experimental-construct, GST - C2A * mutant is an experimental-construct, Biacore AB is a brand, glutathione - S - transferase is a protein-family, GST is an experiment-tag, GST - agarose beads is a reagent

1.0alpha7.train.1355_task1

Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please typing these entity words according to sentence: Lc753 - 893, II - III loop, domains II - III, CaV1.2 α1, GST - C2A wt, GST - C2A * mutant, Biacore AB, glutathione - S - transferase, GST, GST - agarose beads Options: protein-family, brand, experimental-construct, protein-domain, experiment-tag, reagent, protein, protein-region

[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]

The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.

[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]

[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]

Lc753 - 893, II - III loop, domains II - III, CaV1.2 α1, GST - C2A wt, GST - C2A * mutant, Biacore AB, glutathione - S - transferase, GST, GST - agarose beads

1.0alpha7.train.1355_task2

Sentence: The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-region", "I-protein-region", "I-protein-region", "I-protein-region", "O", "O", "B-protein-domain", "I-protein-domain", "I-protein-domain", "I-protein-domain", "O", "O", "B-protein", "I-protein", "O", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-brand", "I-brand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "I-protein-family", "O", "B-experiment-tag", "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O" ]

The affinity of Lc753-893, the II-III loop that links domains II-III of the CaV1.2 α1 subunit (32) and GST-C2A wt (31) or GST-C2A* mutant (17) was determined using (i) Biacore 3000 system (Biacore AB) based on surface plasmon resonance methodology and (ii) glutathione-S-transferase (GST) binding assay using GST-agarose beads.

[ "The", "affinity", "of", "Lc753", "-", "893", ",", "the", "II", "-", "III", "loop", "that", "links", "domains", "II", "-", "III", "of", "the", "CaV1.2", "α1", "subunit", "(", "32", ")", "and", "GST", "-", "C2A", "wt", "(", "31", ")", "or", "GST", "-", "C2A", "*", "mutant", "(", "17", ")", "was", "determined", "using", "(", "i", ")", "Biacore", "3000", "system", "(", "Biacore", "AB", ")", "based", "on", "surface", "plasmon", "resonance", "methodology", "and", "(", "ii", ")", "glutathione", "-", "S", "-", "transferase", "(", "GST", ")", "binding", "assay", "using", "GST", "-", "agarose", "beads", "." ]

[ "protein-family", "reagent", "experimental-construct", "protein-domain", "protein-region", "brand", "protein", "experiment-tag" ]

cardiomyopathy is an umlsterm, dilatation is an umlsterm, ventricles is an umlsterm, causes is an umlsterm, sequela is an umlsterm, myocarditis is an umlsterm, virus is an umlsterm, causes is an umlsterm, metabolic disorders is an umlsterm, adriblastintherapy is an umlsterm, cardiomyopathy is an umlsterm, congestive heart failure is an umlsterm, complications is an umlsterm, Diagnosis is an umlsterm, invasive procedures is an umlsterm, causes is an umlsterm, therapeutic is an umlsterm, Therapy is an umlsterm, digitalis is an umlsterm, diuretics is an umlsterm, anticoagulation is an umlsterm, prognosis is an umlsterm, survival is an umlsterm, survival is an umlsterm, cardiomyopathy is an umlsterm, heart transplantation is an umlsterm

MonatsschriftKinderheilkunde.71450218.eng.abstr_task0

Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .

[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]

[ "umlsterm" ]

cardiomyopathy is an umlsterm, dilatation is an umlsterm, ventricles is an umlsterm, causes is an umlsterm, sequela is an umlsterm, myocarditis is an umlsterm, virus is an umlsterm, causes is an umlsterm, metabolic disorders is an umlsterm, adriblastintherapy is an umlsterm, cardiomyopathy is an umlsterm, congestive heart failure is an umlsterm, complications is an umlsterm, Diagnosis is an umlsterm, invasive procedures is an umlsterm, causes is an umlsterm, therapeutic is an umlsterm, Therapy is an umlsterm, digitalis is an umlsterm, diuretics is an umlsterm, anticoagulation is an umlsterm, prognosis is an umlsterm, survival is an umlsterm, survival is an umlsterm, cardiomyopathy is an umlsterm, heart transplantation is an umlsterm

MonatsschriftKinderheilkunde.71450218.eng.abstr_task1

Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please typing these entity words according to sentence: cardiomyopathy, dilatation, ventricles, causes, sequela, myocarditis, virus, causes, metabolic disorders, adriblastintherapy, cardiomyopathy, congestive heart failure, complications, Diagnosis, invasive procedures, causes, therapeutic, Therapy, digitalis, diuretics, anticoagulation, prognosis, survival, survival, cardiomyopathy, heart transplantation Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .

[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]

[ "umlsterm" ]

cardiomyopathy, dilatation, ventricles, causes, sequela, myocarditis, virus, causes, metabolic disorders, adriblastintherapy, cardiomyopathy, congestive heart failure, complications, Diagnosis, invasive procedures, causes, therapeutic, Therapy, digitalis, diuretics, anticoagulation, prognosis, survival, survival, cardiomyopathy, heart transplantation

MonatsschriftKinderheilkunde.71450218.eng.abstr_task2

Sentence: Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dilative cardiomyopathy is characterized by dilatation and impaired contraction of the left or both ventricles . In childhood it has often unknown causes or is the sequela of myocarditis with or without virus persistence with or without autoimmunological components . Other causes are systemic or metabolic disorders or a previous adriblastintherapy . Dilative cardiomyopathy is rare . It presents clinically as congestive heart failure , in a quarter of the cases there are thromboembolic complications . Diagnosis is made by echocardiography , but invasive procedures can disclose specific causes and give further therapeutic options . Therapy consists of digitalis , diuretics and ACE-inhibitors . It should be augmented by a careful -blockade and anticoagulation . Concerning the bad prognosis ( 1 year survival 75 % , 5 years survival 60 % ) dilative cardiomyopathy is the most frequent indication for heart transplantation .

[ "Dilative", "cardiomyopathy", "is", "characterized", "by", "dilatation", "and", "impaired", "contraction", "of", "the", "left", "or", "both", "ventricles", ".", "In", "childhood", "it", "has", "often", "unknown", "causes", "or", "is", "the", "sequela", "of", "myocarditis", "with", "or", "without", "virus", "persistence", "with", "or", "without", "autoimmunological", "components", ".", "Other", "causes", "are", "systemic", "or", "metabolic", "disorders", "or", "a", "previous", "adriblastintherapy", ".", "Dilative", "cardiomyopathy", "is", "rare", ".", "It", "presents", "clinically", "as", "congestive", "heart", "failure", ",", "in", "a", "quarter", "of", "the", "cases", "there", "are", "thromboembolic", "complications", ".", "Diagnosis", "is", "made", "by", "echocardiography", ",", "but", "invasive", "procedures", "can", "disclose", "specific", "causes", "and", "give", "further", "therapeutic", "options", ".", "Therapy", "consists", "of", "digitalis", ",", "diuretics", "and", "ACE", "-", "inhibitors", ".", "It", "should", "be", "augmented", "by", "a", "careful", "-blockade", "and", "anticoagulation", ".", "Concerning", "the", "bad", "prognosis", "(", "1", "year", "survival", "75", "%", ",", "5", "years", "survival", "60", "%", ")", "dilative", "cardiomyopathy", "is", "the", "most", "frequent", "indication", "for", "heart", "transplantation", "." ]

[ "umlsterm" ]

miss rates is a Outcome_Other, adenomas is a Outcome_Physical, colonoscopies is a Intervention_Surgical, colonoscopy is a Intervention_Surgical, 183 patients . is a Participant_Sample-size, second colonoscopy is a Intervention_Surgical, overall miss rate for adenomas is a Outcome_Physical, patients with no or one adenoma is a Participant_Condition, variation in sensitivity is a Outcome_Physical, colonoscopic technology is a Intervention_Surgical, Miss rates is a Outcome_Other

89000_task0

Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical

[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .

[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]

miss rates is a Outcome_Other, adenomas is a Outcome_Physical, colonoscopies is a Intervention_Surgical, colonoscopy is a Intervention_Surgical, 183 patients . is a Participant_Sample-size, second colonoscopy is a Intervention_Surgical, overall miss rate for adenomas is a Outcome_Physical, patients with no or one adenoma is a Participant_Condition, variation in sensitivity is a Outcome_Physical, colonoscopic technology is a Intervention_Surgical, Miss rates is a Outcome_Other

89000_task1

Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please typing these entity words according to sentence: miss rates, adenomas, colonoscopies, colonoscopy, 183 patients ., second colonoscopy, overall miss rate for adenomas, patients with no or one adenoma, variation in sensitivity, colonoscopic technology, Miss rates Options: Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Intervention_Surgical

[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .

[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]

miss rates, adenomas, colonoscopies, colonoscopy, 183 patients ., second colonoscopy, overall miss rate for adenomas, patients with no or one adenoma, variation in sensitivity, colonoscopic technology, Miss rates

89000_task2

Sentence: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies . BACKGROUND & AIMS The miss rate of colonoscopy for neoplasms is poorly understood . The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy . METHODS Two consecutive same day colonoscopies were performed in 183 patients . The patients were randomized to undergo the second colonoscopy by the same or a different endoscopist and in the same or different position . RESULTS The overall miss rate for adenomas was 24 % , 27 % for adenomas < or = 5 mm , 13 % for adenomas 6-9 mm , and 6 % for adenomas > or = 1 cm . Patients with two or more adenomas at the first examination were more likely than patients with no or one adenoma detected at the first examination to have one or more adenomas at the second examination ( odds ratio , 3.3 ; 95 % confidence interval , 1.69-6.46 ) . Right colon adenomas were missed more often ( 27 % ) than left colon adenomas ( 21 % ) , but the difference was not significant . There was evidence of variation in sensitivity between endoscopists , but significant miss rates for small adenomas were found among essentially all endoscopists . CONCLUSIONS Using current colonoscopic technology , there are significant miss rates for adenomas < 1 cm even with meticulous colonoscopy . Miss rates are low for adenomas > or = 1 cm . The results suggest the need for improvements in colonoscopic technology .

[ "Colonoscopic", "miss", "rates", "of", "adenomas", "determined", "by", "back", "-", "to", "-", "back", "colonoscopies", ".", "BACKGROUND", "&", "AIMS", "The", "miss", "rate", "of", "colonoscopy", "for", "neoplasms", "is", "poorly", "understood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "miss", "rate", "of", "colonoscopy", "by", "same", "day", "back", "-", "to", "-", "back", "colonoscopy", ".", "METHODS", "Two", "consecutive", "same", "day", "colonoscopies", "were", "performed", "in", "183", "patients", ".", "The", "patients", "were", "randomized", "to", "undergo", "the", "second", "colonoscopy", "by", "the", "same", "or", "a", "different", "endoscopist", "and", "in", "the", "same", "or", "different", "position", ".", "RESULTS", "The", "overall", "miss", "rate", "for", "adenomas", "was", "24", "%", ",", "27", "%", "for", "adenomas", "<", "or", "=", "5", "mm", ",", "13", "%", "for", "adenomas", "6", "-", "9", "mm", ",", "and", "6", "%", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "Patients", "with", "two", "or", "more", "adenomas", "at", "the", "first", "examination", "were", "more", "likely", "than", "patients", "with", "no", "or", "one", "adenoma", "detected", "at", "the", "first", "examination", "to", "have", "one", "or", "more", "adenomas", "at", "the", "second", "examination", "(", "odds", "ratio", ",", "3.3", ";", "95", "%", "confidence", "interval", ",", "1.69", "-", "6.46", ")", ".", "Right", "colon", "adenomas", "were", "missed", "more", "often", "(", "27", "%", ")", "than", "left", "colon", "adenomas", "(", "21", "%", ")", ",", "but", "the", "difference", "was", "not", "significant", ".", "There", "was", "evidence", "of", "variation", "in", "sensitivity", "between", "endoscopists", ",", "but", "significant", "miss", "rates", "for", "small", "adenomas", "were", "found", "among", "essentially", "all", "endoscopists", ".", "CONCLUSIONS", "Using", "current", "colonoscopic", "technology", ",", "there", "are", "significant", "miss", "rates", "for", "adenomas", "<", "1", "cm", "even", "with", "meticulous", "colonoscopy", ".", "Miss", "rates", "are", "low", "for", "adenomas", ">", "or", "=", "1", "cm", ".", "The", "results", "suggest", "the", "need", "for", "improvements", "in", "colonoscopic", "technology", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Surgical", "Participant_Sample-size", "Outcome_Other" ]

Skeletal muscle is an umlsterm, protein is an umlsterm, critical illness is an umlsterm, injury is an umlsterm, muscle is an umlsterm, complications is an umlsterm, patient is an umlsterm, Protein is an umlsterm, turnover is an umlsterm, treatment is an umlsterm, knowledge is an umlsterm, research is an umlsterm

IntensiveMedizin.90360619.eng.abstr_task0

Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .

[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]

[ "umlsterm" ]

Skeletal muscle is an umlsterm, protein is an umlsterm, critical illness is an umlsterm, injury is an umlsterm, muscle is an umlsterm, complications is an umlsterm, patient is an umlsterm, Protein is an umlsterm, turnover is an umlsterm, treatment is an umlsterm, knowledge is an umlsterm, research is an umlsterm

IntensiveMedizin.90360619.eng.abstr_task1

Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please typing these entity words according to sentence: Skeletal muscle, protein, critical illness, injury, muscle, complications, patient, Protein, turnover, treatment, knowledge, research Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .

[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]

[ "umlsterm" ]

Skeletal muscle, protein, critical illness, injury, muscle, complications, patient, Protein, turnover, treatment, knowledge, research

IntensiveMedizin.90360619.eng.abstr_task2

Sentence: Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Skeletal muscle protein breakdown is a dominant feature of critical illness and is believed to be a useful biological response to injury . However the loss of muscle is accompanied by some major difficulties in medical management and complications for the patient . Protein turnover is difficult to study and the catabolic state is resistant to treatment , whether by nutritional or other strategies . This article provides an overview of the current physiological knowledge in this area , questions the usefulness of the catabolic response and highlights some new research worthy of further investigation .

[ "Skeletal", "muscle", "protein", "breakdown", "is", "a", "dominant", "feature", "of", "critical", "illness", "and", "is", "believed", "to", "be", "a", "useful", "biological", "response", "to", "injury", ".", "However", "the", "loss", "of", "muscle", "is", "accompanied", "by", "some", "major", "difficulties", "in", "medical", "management", "and", "complications", "for", "the", "patient", ".", "Protein", "turnover", "is", "difficult", "to", "study", "and", "the", "catabolic", "state", "is", "resistant", "to", "treatment", ",", "whether", "by", "nutritional", "or", "other", "strategies", ".", "This", "article", "provides", "an", "overview", "of", "the", "current", "physiological", "knowledge", "in", "this", "area", ",", "questions", "the", "usefulness", "of", "the", "catabolic", "response", "and", "highlights", "some", "new", "research", "worthy", "of", "further", "investigation", "." ]

[ "umlsterm" ]

cell is a Cell, cell is a Cell, cell is a Cell, tumor is a Cancer, cancer is a Cancer, pancreas is a Organ, tumor is a Cancer, tumor is a Cancer, intron 1 is a Cellular_component, tissues is a Tissue, cell is a Cell, cell is a Cell, foci is a Cell, embryonic fibroblasts is a Cell, tumor is a Cancer

PMID-15833857_task0

Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Organ, Cancer, Cellular_component, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.

[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]

[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]

cell is a Cell, cell is a Cell, cell is a Cell, tumor is a Cancer, cancer is a Cancer, pancreas is a Organ, tumor is a Cancer, tumor is a Cancer, intron 1 is a Cellular_component, tissues is a Tissue, cell is a Cell, cell is a Cell, foci is a Cell, embryonic fibroblasts is a Cell, tumor is a Cancer

PMID-15833857_task1

Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please typing these entity words according to sentence: cell, cell, cell, tumor, cancer, pancreas, tumor, tumor, intron 1, tissues, cell, cell, foci, embryonic fibroblasts, tumor Options: Tissue, Organ, Cancer, Cellular_component, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.

[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]

[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]

cell, cell, cell, tumor, cancer, pancreas, tumor, tumor, intron 1, tissues, cell, cell, foci, embryonic fibroblasts, tumor

PMID-15833857_task2

Sentence: Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.

[ "Mouse", "p10", ",", "an", "alternative", "spliced", "form", "of", "p15INK4b", ",", "inhibits", "cell", "cycle", "progression", "and", "malignant", "transformation", ".", "\n", "The", "INK4", "family", "of", "proteins", "negatively", "regulates", "cell", "cycle", "progression", "at", "the", "G(1)-S", "transition", "by", "inhibiting", "cyclin", "-", "dependent", "kinases", ".", "Two", "of", "these", "cell", "cycle", "inhibitors", ",", "p16(INK4A", ")", "and", "p15(INK4B", ")", ",", "have", "tumor", "suppressor", "activities", "and", "are", "inactivated", "in", "human", "cancer", ".", "Interestingly", ",", "both", "INK4", "genes", "express", "alternative", "splicing", "variants", ".", "In", "addition", "to", "p16(INK4A", ")", ",", "the", "INK4A", "locus", "encodes", "a", "splice", "variant", ",", "termed", "p12", "-", "-specifically", "expressed", "in", "human", "pancreas", "--", "and", "ARF", ",", "a", "protein", "encoded", "by", "an", "alternative", "reading", "frame", "that", "acts", "as", "a", "tumor", "suppressor", "through", "the", "p53", "pathway", ".", "Similarly", ",", "the", "human", "INK4B", "locus", "encodes", "the", "p15(INK4B", ")", "tumor", "suppressor", "and", "one", "alternatively", "spliced", "form", ",", "termed", "as", "p10", ".", "We", "show", "here", "that", "p10", ",", "which", "arises", "from", "the", "use", "of", "an", "alternative", "splice", "donor", "site", "within", "intron", "1", ",", "is", "conserved", "in", "the", "mouse", "genome", "and", "is", "widely", "expressed", "in", "mouse", "tissues", ".", "Similarly", "to", "mouse", "p15(INK4B", ")", ",", "p10", "expression", "is", "also", "induced", "by", "oncogenic", "insults", "and", "transforming", "growth", "factor", "-", "beta", "treatment", "and", "acts", "as", "a", "cell", "cycle", "inhibitor", ".", "Importantly", ",", "we", "show", "that", "mouse", "p10", "is", "able", "to", "induce", "cell", "cycle", "arrest", "in", "a", "p53-dependent", "manner", ".", "We", "also", "show", "that", "mouse", "p10", "is", "able", "to", "inhibit", "foci", "formation", "and", "anchorage", "-", "independent", "growth", "in", "wild", "-", "type", "mouse", "embryonic", "fibroblasts", ",", "and", "that", "these", "antitransforming", "properties", "of", "mouse", "p10", "are", "also", "p53-dependent", ".", "These", "results", "indicate", "that", "the", "INK4B", "locus", ",", "similarly", "to", "INK4A", "-", "ARF", ",", "harbors", "two", "different", "splicing", "variants", "that", "can", "be", "involved", "in", "the", "regulation", "of", "both", "the", "p53", "and", "retinoblastoma", "pathways", ",", "the", "two", "major", "molecular", "pathways", "in", "tumor", "suppression", ".", "\n" ]

[ "Cell", "Organ", "Cellular_component", "Tissue", "Cancer" ]

TNF is a protein, methotrexate is a compound

DS.d50_task0

Sentence: Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomised trials have demonstrated that the efficacy of anti-tumour necrosis factor (TNF) agents is significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA).

[ "Randomised", "trials", "have", "demonstrated", "that", "the", "efficacy", "of", "anti", "-", "tumour", "necrosis", "factor", "(", "TNF", ")", "agents", "is", "significantly", "increased", "by", "concomitant", "methotrexate", "(", "MTX", ")", "in", "rheumatoid", "arthritis", "(", "RA", ")", "." ]

[ "compound", "protein" ]